US20220401375A1 - Protecting tissue and mitigating injury from radiation-induced ionizing events - Google Patents
Protecting tissue and mitigating injury from radiation-induced ionizing events Download PDFInfo
- Publication number
- US20220401375A1 US20220401375A1 US17/890,809 US202217890809A US2022401375A1 US 20220401375 A1 US20220401375 A1 US 20220401375A1 US 202217890809 A US202217890809 A US 202217890809A US 2022401375 A1 US2022401375 A1 US 2022401375A1
- Authority
- US
- United States
- Prior art keywords
- radiation
- genistein
- composition
- exposure
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000116 mitigating effect Effects 0.000 title claims abstract description 12
- 230000005855 radiation Effects 0.000 title claims description 122
- 230000006378 damage Effects 0.000 title description 19
- 208000027418 Wounds and injury Diseases 0.000 title 1
- 208000014674 injury Diseases 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 49
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 169
- 229940045109 genistein Drugs 0.000 claims description 161
- 235000006539 genistein Nutrition 0.000 claims description 161
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 160
- 239000000203 mixture Substances 0.000 claims description 130
- 239000002245 particle Substances 0.000 claims description 31
- 239000000725 suspension Substances 0.000 claims description 25
- 241000282414 Homo sapiens Species 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- 239000003085 diluting agent Substances 0.000 claims description 15
- 239000002736 nonionic surfactant Substances 0.000 claims description 14
- 208000001395 Acute radiation syndrome Diseases 0.000 claims description 13
- 206010068142 Radiation sickness syndrome Diseases 0.000 claims description 12
- 229920003169 water-soluble polymer Polymers 0.000 claims description 12
- 239000000872 buffer Substances 0.000 claims description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 238000009826 distribution Methods 0.000 claims description 6
- 206010016654 Fibrosis Diseases 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 230000002939 deleterious effect Effects 0.000 claims description 5
- 230000004761 fibrosis Effects 0.000 claims description 5
- 230000003111 delayed effect Effects 0.000 claims description 4
- 239000007897 gelcap Substances 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 230000000626 neurodegenerative effect Effects 0.000 claims description 2
- 230000005865 ionizing radiation Effects 0.000 abstract description 48
- 230000000694 effects Effects 0.000 abstract description 38
- 239000000463 material Substances 0.000 abstract description 12
- 238000009472 formulation Methods 0.000 description 29
- 206010073306 Exposure to radiation Diseases 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 230000002354 daily effect Effects 0.000 description 10
- 239000002105 nanoparticle Substances 0.000 description 10
- -1 HZE ions Chemical class 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 230000005778 DNA damage Effects 0.000 description 7
- 231100000277 DNA damage Toxicity 0.000 description 7
- 238000001959 radiotherapy Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 4
- 102000000509 Estrogen Receptor beta Human genes 0.000 description 4
- 108010041356 Estrogen Receptor beta Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000009931 harmful effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 230000004992 fission Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229920001993 poloxamer 188 Polymers 0.000 description 3
- 229940044519 poloxamer 188 Drugs 0.000 description 3
- 239000000651 prodrug Chemical class 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000000348 solid-phase epitaxy Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 2
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 2
- 235000007689 Borago officinalis Nutrition 0.000 description 2
- 240000004355 Borago officinalis Species 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000037048 Prodromal Symptoms Diseases 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 208000003386 Radiation-Induced Neoplasms Diseases 0.000 description 2
- 208000028990 Skin injury Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 229940090047 auto-injector Drugs 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000002661 proton therapy Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000004223 radioprotective effect Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000226021 Anacardium occidentale Species 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000068645 Carya illinoensis Species 0.000 description 1
- 235000009025 Carya illinoensis Nutrition 0.000 description 1
- 235000019492 Cashew oil Nutrition 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 244000257039 Duranta repens Species 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 241000208467 Macadamia Species 0.000 description 1
- 235000019493 Macadamia oil Nutrition 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000019495 Pecan oil Nutrition 0.000 description 1
- 235000019496 Pine nut oil Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920003080 Povidone K 25 Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- CIOAGBVUUVVLOB-NJFSPNSNSA-N Strontium-90 Chemical compound [90Sr] CIOAGBVUUVVLOB-NJFSPNSNSA-N 0.000 description 1
- NINIDFKCEFEMDL-AKLPVKDBSA-N Sulfur-35 Chemical compound [35S] NINIDFKCEFEMDL-AKLPVKDBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 229920001938 Vegetable gum Polymers 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000020226 cashew nut Nutrition 0.000 description 1
- 239000010467 cashew oil Substances 0.000 description 1
- 229940059459 cashew oil Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000000193 eyeblink Effects 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000013016 formulated drug substance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002272 genistein Chemical class 0.000 description 1
- 230000008826 genomic mutation Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000009629 growth pathway Effects 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000010884 ion-beam technique Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000010469 macadamia oil Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000010470 pecan oil Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000010490 pine nut oil Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229940124553 radioprotectant Drugs 0.000 description 1
- 230000001950 radioprotection Effects 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 229910052704 radon Inorganic materials 0.000 description 1
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- DNYWZCXLKNTFFI-UHFFFAOYSA-N uranium Chemical compound [U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U] DNYWZCXLKNTFFI-UHFFFAOYSA-N 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Definitions
- This document relates to materials and methods for reducing, preventing, or mitigating acute and chronic biological effects of exposure to ionizing radiation.
- ARS acute radiation syndrome
- ARS is an illness caused by irradiation of the body (either the entire body or a significant portion thereof) to ionizing radiation.
- ARS includes four phases: a prodromal period, a latent period, and a period of illness, followed by recovery or death.
- prodromal period individuals can experience loss of appetite, nausea, vomiting, fatigue, and diarrhea, and additional symptoms such as fever and respiratory distress may occur after exposure to extremely high doses. These symptoms typically disappear after a day or two, and a symptom-free period follows, with a length depending on the size of the radiation dose.
- the third period, overt illness, can include characteristics such as infection, electrolyte imbalance, diarrhea, bleeding, and cardiovascular collapse.
- death or recovery follows the illness. Delayed effects of acute radiation syndrome (DEARE) also can occur from non-lethal but high acute doses of ionizing radiation. Symptoms are largely tissue-specific, but generally manifest as degenerative diseases, including cardiovascular disease, cognitive impairment, and fibrosis of various tissues, for example. Acute or chronic exposure to low doses of radiation also is a concern. Low doses of radiation, while not being acutely toxic, may still cause irreparable genomic mutations that can increase the risk of cancer later in life, as well as the risk of cardiovascular disease, tissue fibrosis, inflammation, and neurodegenerative conditions.
- compositions containing genistein can be useful as countermeasures against the ionizing effects of radiation, and particularly against the ionizing effects of neutron and charged particle radiation.
- Genistein has significant cell-signaling activities that affect how cells respond to radiation damage.
- compositions e.g., suspension formulations
- genistein nanoparticles as the active ingredient may be used as countermeasures against exposure to ionizing radiation, decreasing DNA damage, oxidation, and other adverse effects.
- the methods described herein can be used to mitigate acute and delayed effects in individuals exposed to radiation that induces ionizing events.
- the methods described herein also can be used to protect individuals at risk of exposure to radiation that induces ionizing events, preventing or reducing the adverse effects should exposure to such radiation occur.
- this document features a method for preventing, reducing, or mitigating, in a subject in need thereof, one or more effects of exposure to proton radiation.
- the method can include administering to the subject a composition containing nanoparticulate genistein, where the subject is identified as having been exposed to proton radiation or as being at risk of exposure to proton radiation, and where the composition has a nanoparticulate genistein concentration between about 250 mg/mL and about 500 mg/mL.
- the subject can be a human (e.g., a cancer patient who will undergo proton radiation therapy, an individual who will be traveling to outer space, a first responder, or a member of the military).
- the genistein nanoparticulate composition can have a particle size distribution characterized by a d(0.5) less than or equal to 0.3 ⁇ m.
- the composition further can contain one or more pharmaceutically acceptable excipients forming a suspension medium, where the one or more pharmaceutically acceptable excipients include a water soluble polymer containing a polyvinylpyrrolidone.
- the one or more pharmaceutically acceptable excipients can include a nonionic surfactant, a diluent, or a buffer.
- the nonionic surfactant can be present in an amount ranging from about 0.01% to about 10% by weight (w/w).
- the amount of water soluble polymer can be about 0.5% to about 15% (w/w).
- the composition can contain a diluent and a preservative, and optionally can further comprise a non-ionic surfactant.
- the nanoparticulate genistein can be present in the composition at an amount ranging up to about 50% (w/w), or at an amount of about 20% to about 35% (w/w).
- the composition can have a nanoparticulate genistein concentration of about 325 mg/mL.
- the composition can have a pH of about 2 to about 12.
- the composition can be formulated as a tablet, a capsule, or a gel cap.
- the method can include administering the composition orally, intramuscularly, subcutaneously, or intravenously.
- the method can include administering the composition about 2 hours before potential exposure to the proton radiation, within about 48 hours before potential exposure to the proton radiation, or within about 24 hours before potential exposure to the proton radiation.
- The can include administering the composition on a daily basis.
- the method can include administering the composition at a dose of about 0.5 g to about 2.5 g, or at a dose of about 1 g to about 1.5 g.
- the method can include administering the composition within about 60 minutes after exposure to the proton radiation, or within about 24 hours after exposure to the proton radiation.
- the method can include administering the composition at a dose of about 0.5 g to about 2.5 g per day for about 1 day to about 90 days.
- this document features the use of a composition containing nanoparticulate genistein for preventing, reducing, or mitigating, in a subject in need thereof, one or more effects of exposure to proton radiation, wherein the subject is identified as having been exposed to proton radiation or as being at risk of exposure to proton radiation, and wherein the composition has a nanoparticulate genistein concentration between about 250 mg/mL and about 500 mg/mL.
- the subject can be a human.
- the subject can be a cancer patient who will undergo proton radiation therapy, a subject who will be traveling to outer space, a first responder, or a member of the military.
- the genistein nanoparticulate composition can have a particle size distribution characterized by a d(0.5) less than or equal to 0.3 ⁇ m.
- the composition can further contain one or more pharmaceutically acceptable excipients forming a suspension medium, wherein the one or more pharmaceutically acceptable excipients include a water soluble polymer comprising a polyvinylpyrrolidone.
- the one or more pharmaceutically acceptable excipients can include a nonionic surfactant, a diluent, or a buffer.
- the nonionic surfactant can be present in an amount ranging from about 0.01% to about 10% by weight (w/w).
- the amount of water soluble polymer can be about 0.5% to about 15% (w/w).
- the composition can contain a diluent and a preservative.
- the composition can further contain a non-ionic surfactant.
- the nanoparticulate genistein can be present in the composition at an amount ranging up to about 50% (w/w), or at an amount of about 20% to about 35% (w/w).
- the composition can have a nanoparticulate genistein concentration of about 325 mg/mL.
- the composition can have a pH of about 2 to about 12.
- the composition can be formulated as a tablet, a capsule, or a gel cap.
- the composition can be formulated for oral, intramuscular, subcutaneous, or intravenous use.
- the composition can be formulated for administration about 2 hours before potential exposure to the proton radiation, formulated for administration within about 48 hours before potential exposure to the proton radiation, or formulated for administration within about 24 hours before potential exposure to the proton radiation.
- the composition can be formulated for administration on a daily basis.
- the composition can be formulated for administration at a dose of about 0.5 g to about 2.5 g, or at a dose of about 1 g to about 1.5 g.
- the composition can be formulated for administration within about 60 minutes after exposure to the proton radiation, or for administration within about 24 hours after exposure to the proton radiation.
- the composition can be formulated for administration at a dose of about 0.5 g to about 2.5 g per day for about 1 day to about 90 days.
- FIG. 1 is a schematic depicting how genistein may mitigate the deleterious effects of ionizing radiation.
- x-rays generally mediate their damaging effects via indirect/oxidative effects, as the ionization of water can create reactive oxygen species (ROS).
- ROS reactive oxygen species
- Free radical scavenging by genistein may prevent this damage.
- Particle radiation involving a particles, ⁇ particles, neutrons, and protons typically causes moderate amounts of both indirect and direct damage, while high energy nuclei (HZE) radiation exerts the majority of its negative consequences via direct effects.
- HZE high energy nuclei
- the physical properties of these particles tend to cause a significant amount of secondary ionization events (delta rays) that concentrate the damage caused by the radiation along the beam path.
- Genistein's affinity for estrogen receptor type ⁇ (ER ⁇ ) over ER ⁇ generally is antagonistic to ER signaling, and suppresses growth pathways in favor of activating cellular checkpoints, which can give cells sufficient time to enact DNA repair. This may be replicated by genistein's tyrosine kinase inhibition, which also is causative of delaying the cell cycle in favor of DNA repair following cellular damage.
- FIG. 2 is a western blot with heart and lung tissue extracted from animals that were treated with or without genistein [200 mg/kg subcutaneously (s.c.)] and then exposed to 6 Gy high LET proton radiation 24 hours after treatment.
- the indicated tissues were harvested 3 days later.
- the levels of p53 (a DNA damage response protein) and ⁇ H2AX (a direct measurement of DNA damage) were measured and compared to a tubulin control.
- genistein treatment prevented a marked increase in p53 levels in response to the radiation exposure.
- Genistein treatment also was correlated with lower levels of ⁇ H2AX.
- FIG. 3 A is a graph plotting quantification of the western blot data for heart tissue as shown in FIG. 2 .
- FIG. 3 B is a graph plotting quantification of the western blot data for lung tissue as shown in FIG. 2 .
- FIGS. 4 A, 4 B, and 4 C are graphs plotting the levels of CXCL1 cytokine ( FIG. 4 A ), granulocyte colony stimulating factor (G-CSF; FIG. 4 B ), and tumor necrosis factor alpha (TNF ⁇ ; FIG. 4 C ) in blood from mice injected with 200 mg/kg genistein (s.c.) 24 hours prior to exposure to 6 Gy high LET proton radiation.
- blood was drawn from mice on the indicated days following radiation exposure, and the levels of cytokines were assayed.
- FIG. 5 is a graph plotting the number of live human cardiomyocytes after treatment of the cells with genistein 24 hours before exposure to various doses of mixed field (32% neutron, 68% gamma) radiation (henceforth referred to as “MF” radiation). Live cell counts were performed 3 days after radiation exposure. The genistein-treated cells exhibited increased survival after exposure to multiple doses of MF radiation. These data imply that genistein treatment can mitigate damage from MF radiation that includes particle radiation.
- mixed field 32% neutron, 68% gamma
- ionizing radiation refers to forms of radiation that can induce ionizing events within a cell. Individuals may encounter various forms of ionizing radiation, including alpha, beta, neutron, gamma, proton, and x-ray radiation. Ionizing radiation forms ions in cells of the tissues through which it passes, by removing electrons from atoms and molecules. Different types of radiation have varying levels of energy—typically, the more energy a type of radiation has, the more deeply it can penetrate into tissue.
- Each type of ionizing radiation has a typical source.
- alpha, beta, and gamma radiation are all created by the natural process of radioactive decay.
- Neutron radiation generally is caused by atomic fission or fusion, and may be encountered in nuclear power plants, in cosmic or high-altitude flight, or from industrial radioactive sources.
- X-rays are man-made and are generated for clinical purposes.
- gamma rays are high energy photons, and have no appreciable mass or charge.
- X-rays also are high energy photons, but are distinguished by their source since they are generally created by man-made instruments.
- non-gamma types of ionizing radiation consist of various atomic particles, including neutrons, protons, alpha particles, beta particles, and high energy nuclei (HZE), and have distinct physical properties, including the mass of each particle. Because these non-photonic, particle types of radiation all have mass and energy, they can be related to one another by their linear energy transfer (LET), which describes how much energy an ionizing particle transfers to material that it traverses, per unit distance.
- LET linear energy transfer
- Alpha radiation consists of ejected helium nuclei, which are heavy, very short-range particles containing two protons and two neutrons. Most alpha radiation is not able to penetrate human skin, although alpha-emitting materials can be harmful to humans if inhaled, swallowed, or absorbed through open wounds. Examples of alpha emitters include radium, radon, uranium, and thorium.
- Beta radiation consists of ejected electrons or positrons, which are light, short-range particles that may travel several feet in air. Beta radiation has the ability to penetrate human skin to the “germinal layer” at which new skin cells are produced. Beta-emitting materials that are allowed to remain on the skin for a prolonged period of time may cause skin injury, and may be harmful if deposited internally. Examples of beta emitters include strontium-90, carbon-14, tritium, and sulfur-35.
- Neutron radiation consists of free neutrons released from atoms as a result of nuclear fission or nuclear fusion. Free neutrons have no charge, but can react with nuclei of other atoms to form new isotopes, which, in turn, can produce radiation.
- Proton radiation can be generated using a particle accelerator to produce a beam of protons.
- Protons have a relatively large mass, and all protons of a given energy have a certain range of penetration into tissue. Because of this feature, proton radiation can be useful for highly targeted treatment of tumors.
- Proton radiation also is a significant component of the ionizing radiation produced by the sun.
- HZE radiation consists of atomic nuclei with an atomic mass greater than helium that have no orbiting electrons, and thus have a charge of greater than +2. They can be generated by large particle accelerators, and are only found in nature as a component of galactic cosmic radiation, presumed to be generated mainly by supernovas beyond Earth's solar system. Common HZE ions include C +6 , O +8 , and Fe +26 . The frequency of HZE nucleons is inversely proportional to their atomic number, but the relative biological effect scales with increasing atomic number. For example, while Fe +26 may only makeup 1% of galactic cosmic radiation, it could account for up to 50% of the biological damage from exposure to such radiation.
- MF radiation typically is encountered as a mixed field (MF) that contains multiple types of radiation, rather than as a single beam exposure of the type commonly created by man.
- MF radiation can include various combinations of proton radiation, neutron radiation, alpha and/or beta radiation, and photon radiation.
- an unshielded nuclear fission event e.g., an attack or a reactor meltdown
- individuals would likely be exposed to a miasma of photons, neutrons, alpha, and beta particles.
- RBE Relative Biological Effect
- ionizing radiation countermeasures are free-radical scavengers, which can detoxify radiation exposure by limiting oxidative damage. While this may be an avenue for treatment of photon radiation exposure, the complex biological damage resulting from, for example, HZE radiation limits the effectiveness of countermeasures that possess antioxidant activity. Thus, the efficacy of a countermeasure against some forms of ionizing radiation does not predict its efficacy against all forms of ionizing radiation.
- ARS nuclear cortisol
- DEARE degenerative effects on tissue, such as fibrosis.
- Ionizing radiation encountered during space missions also can present potential health problems for astronauts, with a significant risk of ARS (Wu et al., “Risk of Acute Radiation Syndromes Due to Solar Particle Events.” In: McPhee and Charles (Eds.), Human Health and Performance Risks of Space Exploration Missions , NASA, pp. 171-190, 2009).
- ARS effects from SPE exposure in space flight include prodromal effects (nausea, vomiting, anorexia, and fatigue), skin injury, and depletion of blood-forming organs.
- SPEs are of lower energy than are GCRs, and shielding typically is an effective countermeasure to SPEs inside spacecraft. Exposure is likely to be higher during extravehicular activity, however, and the magnitude of ARS risks may be increased due to factors such as background GCR exposure (Wu et al., supra).
- ionizing radiation Given the health risks of ionizing radiation, it is important to mitigate the effects of exposure in subjects who have been exposed to, or are at risk of exposure to, ionizing radiation. Those who are most likely to be exposed to ionizing radiation include, for example, cancer patients treated with radiation therapy (e.g., gamma radiation or proton radiation), workers in nuclear power plants, military personnel, and first responders to nuclear incidents (e.g., medical personnel and hazmat teams). Another group of individuals who may encounter ionizing radiation includes astronauts, since ionizing radiation exists in outer space.
- radiation therapy e.g., gamma radiation or proton radiation
- workers in nuclear power plants e.g., military personnel
- first responders to nuclear incidents e.g., medical personnel and hazmat teams.
- Another group of individuals who may encounter ionizing radiation includes astronauts, since ionizing radiation exists in outer space.
- GCR galactic cosmic rays
- SPEs which are produced in the solar corona and are associated with flares, can be difficult to predict beyond a matter of hours in advance, and can last for hours or even days (Hassler et al., Science 343(6169), DOI: 10.1126/science.1244797, 2014).
- compositions containing genistein can be used as medical countermeasures that can reduce or prevent detrimental effects of exposure to ionizing radiation, and in some cases, can increase survival after such exposure.
- Genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one (IUPAC), 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one, 5,7,4′-trihydroxyisoflavone, 4′,5,7-trihydroxyisoflavone) is a phytoestrogen in the category of isoflavones. Its chemical structure is shown in Formula (1):
- Genistein is one of several known isoflavones that are normally found in plants.
- the main sources of natural genistein are soybeans and other legumes.
- Genistein also is commercially available, and may be obtained in synthetic, purified form (e.g., from DSM Nutritional Products, Inc., Parsippany, N.J.).
- Genistein's radioprotective properties may be mediated, at least in part, by its activity as a selective agonist of estrogen receptor beta (ER ⁇ ). ER ⁇ activation can inhibit cell proliferation via upregulation of its target genes, which encode cellular checkpoint and damage repair proteins.
- Other pharmacological properties of genistein that may mediate radioprotection include tyrosine kinase inhibition and free-radical scavenging, as depicted in FIG. 1 .
- a formulation of genistein that can be distinguished from other radioprotectants and sources of genistein can be used to mitigate toxicities from various sources of radiation, including proton radiation (e.g., high LET proton radiation).
- a composition can include genistein nanoparticles, which can have improved oral and/or parenteral bioavailability as compared to genistein that is not in nanoparticle form.
- Nanoparticle formulations can contain sub-micron size genistein particles, which can be manufactured using a wet nanomilling process that reduces genistein to a median particle size of less than 0.2 ⁇ m. See, e.g., U.S. Pat. No. 8,551,530.
- the genistein compositions used in the methods provided herein can be formulations that include genistein in a solution containing one or more pharmaceutically acceptable carriers, excipients, and/or diluents.
- the genistein compositions used in the methods provided herein can be suspension formulations that include nanoparticulate genistein suspended in a medium containing one or more pharmaceutically acceptable carriers, excipients, and/or diluents.
- Pharmaceutically acceptable carriers, excipients, and diluents suitable for therapeutic use include those described, for example, in Remington's Pharmaceutical Sciences , Maack Publishing Co. (A. R. Gennaro (ed.), 1985).
- polyethylene glycol (PEG) can be used as a carrier in a composition that also contains genistein that is not in nanoparticle form.
- genistein compositions can include a suspension containing nanoparticulate genistein suspended in a non-aqueous medium, such as an edible plant or animal oil (e.g., olive oil, sunflower oil, corn oil, soy oil, marine oil, coconut oil, palm oil, palm kernel oil, cotton seed oil, safflower oil, sesame oil, peanut oil, almond oil, cashew oil, pecan oil, pine nut oil, macadamia oil, orange oil, flax seed oil, lemon oil, walnut oil, borage oils, fish oils, and dairy derived fats).
- an edible plant or animal oil e.g., olive oil, sunflower oil, corn oil, soy oil, marine oil, coconut oil, palm oil, palm kernel oil, cotton seed oil, safflower oil, sesame oil, peanut oil, almond oil, cashew oil, pecan oil, pine nut oil, macadamia oil, orange oil, flax seed oil, lemon oil, walnut oil, borage oils, fish oils, and dairy derived fats.
- Genistein compositions can, in some embodiments, include a suspension containing nanoparticulate genistein suspended in a medium including one or more water soluble polymers and one or more nonionic surfactants. See, e.g., U.S. Pat. No. 8,551,530.
- Nonionic surfactants can facilitate wetting and aid in preventing agglomeration of the nanoparticulate genistein, for example.
- Suitable nonionic surfactants include, without limitation, polysorbates, poloxamers, polyoxyethylene castor oil derivatives, bile salts, lecithin, 12-hydroxystearic acid-polyethylene glycol copolymer, and the like.
- a genistein composition can include a nonionic surfactant selected from the group consisting of polysorbate 80 (TWEEN® 80), polysorbate 20 (TWEEN® 20), Poloxamer 188, and combinations thereof.
- the total nonionic surfactant content in the genistein compositions provided herein can range from about 0.01% to about 10% by weight (w/w) (e.g., about 0.2% to about 5% (w/w), about 0.2% to about 2% (w/w), about 0.2% to about 1% (w/w), about 0.2% to about 0.6% (w/w), and about 0.2% to about 0.8% (w/w).
- Water soluble polymers can serve to enhance the viscosity of a suspension and/or to stabilize nanoparticulate genistein against particle agglomeration or potential deleterious effects from other formulation components, for example.
- Water soluble polymers are pharmaceutically acceptable polymers that can be dissolved or dispersed in water. Suitable water soluble polymers include, without limitation, vegetable gums (e.g., alginates, pectin, guar gum, and xanthan gum), modified starches, polyvinylpyrrolidone (PVP), hypromellose (HPMC), methylcellulose, and other cellulose derivatives (e.g., sodium carboxymethylcellulose, hydroxypropylcellulose, and the like).
- vegetable gums e.g., alginates, pectin, guar gum, and xanthan gum
- PVP polyvinylpyrrolidone
- HPMC hypromellose
- methylcellulose e.g., sodium carboxymethylcellulose, hydroxypropylcellulose
- the genistein compositions described herein can include a poloxamer (e.g., Poloxamer 188) as a water soluble polymer.
- Poloxamer 188 is both a polymer and surfactant.
- the total water soluble polymer content in a genistein composition as provided herein can range from about 0.5% to about 15% (w/w) [e.g., about 1% to about 10% (w/w), about 10% to about 15% (w/w), about 12% to about 15% (w/w), about 1% to about 8% (w/w), and about 1% to about 5% (w/w)].
- Carriers suitable for use in the genistein formulations described herein also include pharmaceutically acceptable aqueous carriers such as, sterile water, physiologically buffered saline, Hank's solution, and Ringer's solution.
- the formulations also can contain one or more buffers [e.g., one or more citrate buffers, phosphate buffers, tris(hydroxymethyl)aminomethane (TRIS) buffers, and/or borate buffers], to achieve a desired pH and osmolality.
- Injectable pharmaceutical formulations typically have a pH in the range of about 2 to about 12.
- the genistein formulations provided herein can have a pH that falls in a range that more closely approximates physiologic pH (e.g., about 4 to about 8, or about 5 to about 7).
- the genistein compositions provided herein also can include one or more diluents.
- Suitable diluents include those selected from, without limitation, pharmaceutically acceptable buffers, solvents, and surfactants.
- a genistein composition can include PVP (e.g., 5% PVP-K17) and polysorbate 80 (e.g., 0.2% polysorbate 80), as well as phosphate buffered saline (PBS, e.g., 50 nM PBS).
- PVP phosphate buffered saline
- an oral formulation of a genistein composition can contain PVP (e.g., PVP-K25), polysorbate 80 (TWEEN® 80), and one or more preservatives (e.g., methyl paraben, propyl paraben, benzyl alcohol, or any combination thereof).
- a composition can include a diluent such as a sodium chloride solution.
- the particle size distribution of the genistein nanoparticulate composition can be d(0.5) ⁇ 0.50 microns (e.g., d(0.5) ⁇ 0.40 microns, d(0.5) ⁇ 0.30 microns, or d(0.5) ⁇ 0.20 microns). See, e.g., U.S. Pat. No. 8,551,530. It is to be noted that while such genistein formulations are characterized as suspensions, depending on the carriers, excipients, and diluents included in the suspension medium, a measurable amount of genistein also may be dissolved in the suspension medium.
- genistein exhibits low to virtually no solubility in several pharmaceutically acceptable solvents, but a nanoparticulate suspension of genistein as described herein can provide a high concentration of genistein.
- a suspension of nanoparticulate genistein can incorporate genistein in amounts ranging from about 100 mg/mL to about 500 mg/mL (e.g., ranges from about 100 mg/mL to about 400 mg/mL, about 150 mg/mL to about 350 mg/mL, about 200 mg/mL to about 400 mg/mL, about 250 mg/mL to about 350 mg/mL, about 275 mg/mL to about 325 mg/mL, about 300 mg/mL to about 450 mg/mL, or about 350 mg/mL to about 500 mg/mL, or amounts of about 100 mg/mL, about 150 mg/mL, about 200 mg/mL, about 250 mg/mL, about 275 mg/mL, about 300 mg/mL, about 325 mg/mL, about
- a suspension formulation as described herein can include up to about 50% (w/w) genistein [e.g., about 50% (w/w), about 45% (w/w), about 40% (w/w), about 35% (w/w), about 30% (w/w), about 25% (w/w), about 20% (w/w), about 15% (w/w), about 10% (w/w), about 40% to about 50% (w/w), about 35% to about 45%, about 30% to about 40% (w/w), about 25% to about 35% (w/w), about 20% to about 30% (w/w), about 20% to about 35% (w/w), about 15% to about 35%, about 10% to about 30%, or about 10% to about 25%1.
- nanoparticle genistein suspensions can provide increased bioavailability of genistein as compared to the bioavailability of genistein provided by solution formulations (e.g., solutions containing a pharmaceutically acceptable PEG solvent or containing larger sized genistein material).
- solution formulations e.g., solutions containing a pharmaceutically acceptable PEG solvent or containing larger sized genistein material.
- the combination of high genistein loading and significantly increased bioavailability can provide advantages, such as facilitating administration of therapeutically effective amounts of genistein using much lower amounts of formulated drug substance, for example.
- Genistein compositions can be formulated for administration by any suitable method, depending upon whether local or systemic treatment is desired and upon the area to be treated.
- a genistein composition can be formulated for oral administration, parenteral administration (e.g., by subcutaneous, intrathecal, intraventricular, intramuscular, or intraperitoneal injection, or by intravenous drip), pulmonary administration (e.g., by inhalation or insufflation of powders or aerosols or a nebulized mist), or by a combination of routes such as oral and parenteral administration.
- Administration can be rapid (e.g., by injection) or can occur over a period of time (e.g., by slow infusion or administration of slow release formulations, such as from subcutaneous drug depots, slow short term intravenous injections, or slow release oral formulations).
- compositions and formulations for parenteral administration include, for example, sterile solutions (e.g., sterile aqueous solutions or suspensions) that also can contain buffers, diluents, and/or other suitable additives (e.g., penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers).
- sterile solutions e.g., sterile aqueous solutions or suspensions
- suitable additives e.g., penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers.
- Compositions formulated for parenteral delivery can be manufactured according to standard methods to provide sterile compositions deliverable via, for example, intravenous injection or infusion, intravascular injection, subcutaneous injection, or intramuscular injection.
- a genistein formulation (e.g., a suspension of nanoparticulate genistein) can be prepared to have a viscosity suitable for the desired route of parenteral administration, and can be manufactured and packaged in any manner suited to the desired application, including, without limitation, as a formulation deliverable via intravenous injection or infusion, intravascular injection, subcutaneous injection, or intramuscular injection.
- a formulation as described herein can be contained in one or more pre-filled syringes or auto-injectors prepared for administration of a given dose or range of doses of genistein.
- Genistein compositions also can be formulated for oral administration.
- Compositions and formulations for oral administration include, for example, powders or granules, suspensions or solutions in water or non-aqueous media (e.g., suspensions of genistein nanoparticles in edible oil), capsules, gel caps, sachets, and tablets.
- a genistein composition can be prepared as a liquid suspension that can be metered to deliver a desired dose, or can be incorporated into capsules (e.g., gelatin or soft capsules) suitable for delivery of liquid formulations.
- formulations for oral administration can be loaded into prefilled sachets or premetered dosing cups.
- such genistein formulations also can include one or more pharmaceutically acceptable sweetening agents, preservatives, dyestuffs, flavorings, or any combination thereof.
- Genistein compositions useful in the methods described herein can further include any pharmaceutically acceptable genistein salts, esters, or salts of such esters, or any other genistein compound which, upon administration to an animal such as a human, is capable of providing (directly or indirectly) biologically active genistein or an active metabolite or residue thereof.
- pharmaceutically acceptable salts of genistein, prodrugs and pharmaceutically acceptable salts of such prodrugs, and other bioequivalents are provided herein.
- prodrug indicates a therapeutic agent that is prepared in an inactive form and is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions.
- pharmaceutically acceptable salts refers to physiologically and pharmaceutically acceptable salts of genistein (e.g., salts that retain the desired biological activity of genistein without imparting undesired toxicological effects).
- examples of pharmaceutically acceptable salts may include, for example, salts formed with cations (e.g., sodium, potassium, calcium, or polyamines such as spermine), acid addition salts formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, or nitric acid), and salts formed with organic acids (e.g., glucuronic acid, acetic acid, citric acid, oxalic acid, palmitic acid, or fumaric acid).
- genistein may be sulfated or in glucuronic acid form.
- compositions also can include other adjunct components conventionally found in pharmaceutical compositions.
- the compositions also can include compatible, pharmaceutically active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or additional materials useful in physically formulating various dosage forms of the compositions provided herein, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers.
- the composition can be mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings, and aromatic substances. When added, however, such materials should not unduly interfere with the biological activities of the genistein within the composition.
- the formulations can be sterilized if desired.
- This document also provides methods for using genistein compositions as countermeasures against the effects of ionizing radiation.
- Such countermeasures can be used to prevent, reduce, or mitigate effects such as carcinogenesis, damage to the central nervous system, degenerative effects on tissue, and even death.
- this document provides methods for treating a subject to prevent, reduce, or mitigate one or more effects of potential exposure to ionizing radiation.
- the methods can include identifying a subject as being at risk for exposure to ionizing radiation, and administering to the subject an effective dose of a genistein-containing composition.
- the subject can be, for example, a human or a non-human mammal.
- Subjects at risk for exposure to ionizing radiation may be individuals who will undergo radiation therapy (e.g., proton therapy) for cancer, individuals present or likely to be present in an industrial or military setting in which exposure to ionizing radiation could occur, or astronauts.
- such individuals can be treated with a genistein-containing composition prophylactically, before exposure to ionizing radiation has occurred.
- an individual can be treated on a daily or weekly basis (e.g., every day, about six days per week, about five days per week, about four days per week, about three days per week, or about two days per week), before potential exposure to ionizing radiation.
- an individual can be treated within about 1 hour to about 6 days (e.g., within about 5 to 6 days, about 4 to 5 days, about 3 to 4 days, about 60 to 72 hours, about 48 to 60 hours, about 36 to 48 hours, about 24 to 36 hours, about 18 to 24 hours, about 12 to 18 hours, about 10 to 12 hours, about 8 to 10 hours, about 6 to 8 hours, about 4 to 6 hours, about 2 to 4 hours, or about 1 to 2 hours) before potential exposure, such as before entering an area of increased risk for exposure to ionizing radiation or before an imminent SPE event, to prevent or reduce potential harmful effects, should such exposure occur.
- potential exposure such as before entering an area of increased risk for exposure to ionizing radiation or before an imminent SPE event, to prevent or reduce potential harmful effects, should such exposure occur.
- this document provides methods for treating a subject to reduce, prevent, or mitigate one or more effects of exposure to ionizing radiation.
- the methods can include identifying a subject as having been exposed to ionizing radiation (e.g., exposed once, exposed more than once, such as for fractionated proton radiation therapy for cancer treatment, or exposed continuously over a period of time), and administering to the subject an effective dose of a genistein-containing composition.
- the subject can be a human or a non-human mammal, and can be an individual exposed to ionizing radiation in a medical setting (e.g., a cancer patient treated with proton radiation therapy) or in an industrial or military setting, or in outer space.
- the genistein composition can be administered within about four weeks or less (e.g., within about three weeks, two weeks, or one week), or within about 96 hours or less (e.g., within about 72 to 96 hours, about 48 to 72 hours, about 24 to 48 hours, about 20 to 24 hours, about 18 to 20 hours, about 16 to 18 hours, about 12 to 16 hours, about 8 to 12 hours, about 6 to 8 hours, about 4 to 6 hours, or about 2 to 4 hours), or within about 60 minutes or less (e.g., within about 45 to 60 minutes, about 30 to 45 minutes, about 15 to 30 minutes, about 10 to 15 minutes, or about 5 to 10 minutes) after exposure.
- the genistein composition can be administered within about four weeks or less (e.g., within about three weeks, two weeks, or one week), or within about 96 hours or less (e.g., within about 72 to 96 hours, about 48 to 72 hours, about 24 to 48 hours, about 20 to 24 hours, about 18 to 20 hours, about 16 to 18 hours, about 12 to
- Administration can continue on an hourly, daily, weekly, or monthly basis to mitigate the effects of exposure to the ionizing radiation.
- a genistein-containing composition can be administered one or more times daily, every other day, biweekly, weekly, bimonthly, monthly, or less often, for any suitable length of time after exposure to the radiation has occurred (e.g., for about a week, about two weeks, about three weeks, about a month, about six weeks, about two months, about three months, about six months, about a year, or more than a year after exposure).
- the methods provided herein include administering to a subject a composition that contains genistein in any formulation suitable to deliver an effective dose of genistein to the subject, where the dose is effective to prevent, reduce, or mitigate effects of the ionizing radiation to which the subject has been or may be exposed.
- a dose administered that is “effective to reduce” the effects of the radiation is a dose that is sufficient to decrease one or more effects of exposure (should such exposure occur) by at least ten percent (e.g., at least ten percent, at least 25 percent, at least 50 percent, or at least 75 percent) as compared to the level of the effects in a corresponding subject to which the composition was not administered.
- an effective dose can prevent development of one or more effects of exposure to the ionizing radiation.
- a dose administered that is “effective to mitigate” the effects of ionizing radiation is a dose that is sufficient to reduce the effects of exposure by at least ten percent (e.g., at least ten percent, at least 25 percent, at least 50 percent, or at least 75 percent), as compared to a corresponding subject to which the composition was not administered.
- Effective doses e.g., therapeutically or prophylactically effective doses
- a composition can contain genistein (e.g., nanoparticulate genistein or genistein that is not in nanoparticle form), at a concentration between about 100 mg/mL and about 500 mg/mL (e.g., about 100 mg/mL to about 400 mg/mL, about 150 mg/mL to about 350 mg/mL, about 200 mg/mL to about 400 mg/mL, about 250 mg/mL to about 350 mg/mL, about 275 mg/mL to about 325 mg/mL, about 300 mg/mL to about 450 mg/mL, or about 350 mg/mL to about 500 mg/mL).
- genistein e.g., nanoparticulate genistein or genistein that is not in nanoparticle form
- concentration between about 100 mg/mL and about 500 mg/mL (e.g., about 100 mg/mL to about 400 mg/mL, about 150 mg/mL to about 350 mg/mL, about 200 mg/mL to
- compositions containing nanoparticulate genistein can have a particle size distribution characterized by a median diameter [d(0.5)] that is less than or equal to 0.5 ⁇ m (e.g., less than or equal to 0.4 ⁇ m, less than or equal to 0.3 ⁇ m, or less than or equal to 0.2 ⁇ m).
- the composition also can contain one or more other components, as described herein (e.g., one or more pharmaceutically acceptable excipients that form a suspension medium, such as a water soluble polymer, a nonionic surfactant, a diluent, or a buffer).
- the suspension medium may be non-aqueous, such as edible lipids, oils, and fats from plant and animal sources (e.g., olive, corn, soy, marine, coconut, palm, palm kernel, cotton seed, peanut, safflower, sesame, sunflower, almond, cashew, macadamia, pecan, pine nut, walnut, lemon, orange, flax seed, and borage oils).
- plant and animal sources e.g., olive, corn, soy, marine, coconut, palm, palm kernel, cotton seed, peanut, safflower, sesame, sunflower, almond, cashew, macadamia, pecan, pine nut, walnut, lemon, orange, flax seed, and borage oils.
- the administering step can be accomplished via any suitable route.
- a genistein composition containing a solution of genistein or a suspension of genistein nanoparticles can be administered orally or parenterally (e.g., by injection, such as subcutaneous, intravenous, or intramuscular injection).
- a prophylactic or therapeutic dose of a genistein-containing composition can contain about 0.25 g to about 2.5 g of genistein (e.g., about 0.25 g to about 0.3 g, about 0.3 g to about 0.4 g, about 0.4 g to about 0.5 g, about 0.5 g to about 0.75 g, about 0.75 g to about 1 g, about 1 g to about 1.25 g, about 1.25 g to about 1.5 g, about 1.5 g to about 1.75 g, about 1.75 g to about 2 g, about 2 g to about 2.25 g, or about 2.25 g to about 2.5 g).
- genistein e.g., about 0.25 g to about 0.3 g, about 0.3 g to about 0.4 g, about 0.4 g to about 0.5 g, about 0.5 g to about 0.75 g, about 0.75 g to about 1 g, about 1 g to about 1.25 g, about 1.25 g
- a dose of a genistein-containing composition can be effective to achieve a blood concentration of aglycone (unconjugated, non-glucuronidated) genistein of about 0.35 ⁇ M to about 5 ⁇ M (e.g., about 0.5 ⁇ M, about 1 ⁇ M, about 1.5 ⁇ M, about 2 ⁇ M, about 3 ⁇ M, about 4 ⁇ M, about 5 ⁇ M, about 0.35 to about 0.5 ⁇ M, about 0.5 to about 0.75 ⁇ M, about 0.75 to about 1 ⁇ M, about 0.75 to about 1.25 ⁇ M, about 1 to 1.5 ⁇ M, about 1.5 to 2.5 ⁇ M, or about 2.5 to 5 ⁇ M).
- aglycone (unconjugated, non-glucuronidated) genistein of about 0.35 ⁇ M to about 5 ⁇ M (e.g., about 0.5 ⁇ M, about 1 ⁇ M, about 1.5 ⁇ M, about 2 ⁇ M, about 3 ⁇ M, about
- a genistein composition can be administered to a subject at a dose of about 5 mg/kg to about 500 mg/kg (e.g., about 5 to 10 mg/kg, about 10 to 25 mg/kg, about 25 to 50 mg/kg, about 50 mg/kg, about 75 to 100 mg/kg, about 100 to 200 mg/kg, about 200 to 300 mg/kg, about 300 to 400 mg/kg, or about 400 to 500 mg/kg).
- a dose of about 5 mg/kg to about 500 mg/kg e.g., about 5 to 10 mg/kg, about 10 to 25 mg/kg, about 25 to 50 mg/kg, about 50 mg/kg, about 75 to 100 mg/kg, about 100 to 200 mg/kg, about 200 to 300 mg/kg, about 300 to 400 mg/kg, or about 400 to 500 mg/kg.
- the dose can be administered on a daily to weekly to monthly basis or longer (e.g., for about 1 day to about 2 years, such as from 1 to 3 days, 3 to 7 days, 7 to 10 days, 10 to 14 days, 14 to 21 days, 21 to 28 days, 28 to 35 days, 30 to 45 days, 45 to 60 days, two to three months, three to six months, six to nine months, nine months to a year, one to 1.5 years, 1.5 to 2 years, or more than 2 years).
- 1 day to about 2 years such as from 1 to 3 days, 3 to 7 days, 7 to 10 days, 10 to 14 days, 14 to 21 days, 21 to 28 days, 28 to 35 days, 30 to 45 days, 45 to 60 days, two to three months, three to six months, six to nine months, nine months to a year, one to 1.5 years, 1.5 to 2 years, or more than 2 years).
- a therapeutic method can include administering a first dose of genistein for a first period of time after exposure to ionizing radiation, and then administering a second dose of genistein for a second period of time.
- the first dose can be higher than the second dose.
- a method can include administering a genistein-containing composition at a dose of 0.25 g to about 2.5 g per day (e.g., about 0.25 g to about 0.3 g, about 0.3 g to about 0.4 g, about 0.4 g to about 0.5 g, about 0.5 g to about 0.75 g, about 0.75 g to about 1 g, about 1 g to about 1.25 g, about 1.25 g to about 1.5 g, about 1.5 g to about 1.75 g, about 1.75 g to about 2 g, about 2 g to about 2.25 g, or about 2.25 g to about 2.5 g per day) for about 1 day to about 6 months (e.g., about 1 day to about 3 days, about 3 days to about 7 days, about 7 days to about 2 years, such as from 7 to 10 days, 10 to 14 days, 14 to 21 days, 21 to 28 days, 28 to 35 days, 30 to 45 days, 45 to 60 days, two to three months, or three to six months
- This document also provides for the use of genistein compositions as described herein for preventing, reducing, or mitigating one or more effects of exposure to proton radiation in a subject identified as having been exposed to proton radiation or as being at risk of exposure to proton radiation.
- this document provides for the use of genistein in the manufacture of medicaments for preventing, reducing, or mitigating one or more effects of exposure to proton radiation in a subject identified as having been exposed to proton radiation or as being at risk of exposure to proton radiation.
- Genistein formulations can be combined with packaging material and sold as kits for preventing, reducing, or mitigating the effects of exposure to ionizing radiation.
- this document also provides articles of manufacture that can include one or more genistein-containing compositions.
- the articles of manufacture can further include, for example, buffers or other control reagents for reducing, preventing, or monitoring the effects of exposure to ionizing radiation.
- Instructions describing how genistein formulations are effective for preventing, reducing, or mitigating damage from such exposure also can be included in such kits.
- an article of manufacture can include a genistein formulation (e.g., a suspension of nanoparticulate genistein) contained within a means for administration, such as an auto-injector.
- a genistein formulation e.g., a suspension of nanoparticulate genistein
- an auto-injector can contain a suspension of nanoparticulate genistein at a concentration between about 250 mg/mL and about 500 mg/mL, where the genistein nanoparticulate composition has a particle size distribution characterized by a d(0.5) of 0.5 ⁇ m or less (e.g., 0.4 ⁇ m or less, 0.3 ⁇ m or less, or 0.2 ⁇ m or less).
- the genistein composition also can include other components (e.g., one or more pharmaceutically acceptable excipients), as described herein.
- pre-made auto-injectors can be obtained commercially, filled with a genistein nanoparticulate composition, and packaged as a kit for preventing, reducing, or mitigating the effects of exposure to ionizing radiation.
- mice were prophylactically administered genistein (200 mg/kg) via s.c. injection 24 hours prior to radiation exposure. Appropriate sham radiation and vehicle controls were applied. Radiation exposures of 6 Gy with high-LET protons [50 MeV fully modulated spread-out Bragg peak (SOBP)] were utilized. The following parameters were examined:
- DNA damage in tissues Lungs and heart were surgically removed and subjected to thin-slice sectioning, followed by western blot analysis for the DNA damage markers p53 and ⁇ H2AX (an effective measure of proton radiation-induced biological damage; see, Liu et al., Radiation Oncology 91(5):1081-1089, 2015), as well as tubulin control.
- Genistein ameliorated the effects of proton radiation on expression of these markers ( FIGS. 2 , 3 A, and 3 B ), indicating its ability to mitigate the toxicity of proton radiation.
- Cytokine response Peripheral blood was taken from the treated and irradiated mice 3, 6, and 12 days after radiation exposure, and assessed using a multi-cytokine LUMINEX® panel to evaluate the global inflammatory cytokine response. As shown in FIGS. 4 A, 4 B, and 4 C , specific cytokine responses were reduced by genistein treatment. In particular genistein mitigated the effects of proton radiation on expression of CXCL1 cytokine ( FIG. 4 A ), G-CSF ( FIG. 4 B ), and TNF ⁇ ( FIG. 4 C ).
- genistein Human cardiomyocytes were treated with genistein 24 hours before exposure to various doses of mixed field (“MF,” 32% neutron, 68% gamma) radiation. Live cell counts were performed 3 days after radiation exposure. The genistein-treated cells exhibited increased survival after exposure to multiple doses of MF radiation ( FIG. 5 ). These data imply that genistein treatment can mitigate damage from MF radiation that includes particle radiation, and indicate that genistein is consistent in its radioprotective effects.
- MF mixed field
- a cancer-prone genetic mouse model is utilized to determine if oral administration of 200 mg/kg genistein prevents an increased incidence in radiation-induced cancer after exposure to simulated space radiation.
- the space radiation simulations include various single ion beams, and mixed fields therein, which are produced at Brookhaven National Laboratory to simulate various spectra of space radiation. Readouts include the incidence of cancers of various tissues in each animal, overall survival, and lifespan.
- Cognitive defects from ionizing radiation are known to result in humans undergoing radiotherapy for brain tumors.
- subjects likely to be exposed to various spectra of ionizing radiation are treated with oral genistein at a dose sufficient to achieve a blood concentration of aglycone (unconjugated, non-glucuronidated) genistein of about 1 ⁇ M.
- Consumption of genistein can be beneficial to mitigating such cognitive toxicity if it is consumed before, during, and/or after radiation exposure.
- Radiation exposure could range from clinical proton therapy in cancer patients to GCR exposure in space-travelling astronauts.
- the protective capacity of genistein on cognitive function is tested using standard cognitive tests.
- Genistein 200 to 400 mg/kg is orally administered to mice up to 7 days before radiation exposure, and possibly continuing for up to about 6 weeks after radiation exposure.
- the animals are subjected to validated cognitive function tests, such as the “Delayed, Non-Matching to Place Task,” or the “Conditioned Eyeblink Reflex,” as well as brain histopathological analyses to be conducted at necropsy of the test subject.
- mice are prophylactically orally gavaged with a daily dose of 400 mg/kg genistein, starting one to six days prior to radiation exposure.
- the prophylactic dose regimen consists of either a single daily dose of 400 mg/kg, or two daily doses of 200 mg/kg each.
- Appropriate sham radiation and vehicle controls are applied.
- the mice are sacrificed for analysis either 4 hours or 16 days after radiation treatment, and assessed for the parameters listed below.
- Study groups include five mice per condition, with two time points and two dosing schemes, requiring 30 animals/experiment.
- the in vivo studies include analysis of any or all of the following parameters.
- CBC Complete blood cell
- Cytokine response Peripheral blood is taken from the animals and assessed using a multi-cytokine LUMINEX® panel to assess the global inflammatory cytokine response. Peripheral blood is collected for cytokine analysis 4 hours and 16 days post radiation exposure.
- DNA damage in tissues Lungs, liver, and bowel from sacrificed animals (4 hours and 16 days post radiation exposure) are surgically removed and subjected to thin-slice sectioning, followed by immunohistological analysis for ⁇ H2AX, which has been demonstrated to be an effective measure of proton radiation-induced biological damage (Liu et al., Radiation Oncology 91(5):1081-1089, 2015). Additionally, pathological parameters such as fibrosis and evidence of inflammation are qualitatively assessed. Tissue analysis is performed on sections from groups of animals demonstrating therapeutic efficacy by CBC measures.
- DNA damage markers in white blood cells Peripheral blood is collected at 4 hours and 16 days post radiation exposure. White blood cells are purified and assessed for DNA damage markers, such as p53 and ⁇ H2AX, which are detected by FACS or western blot.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Materials and methods for reducing, preventing, or mitigating the effects of exposure to ionizing radiation are provided herein.
Description
- This application is a continuation of U.S. application Ser. No. 16/488,325, filed on Aug. 23, 2019, which is a National Stage application under 35 U.S.C. § 371 of International Application No. PCT/US2018/019507, having an International Filing Date of Feb. 23, 2018, which claims benefit of priority from U.S. Provisional Application Ser. No. 62/463,340, filed on Feb. 24, 2017.
- This document relates to materials and methods for reducing, preventing, or mitigating acute and chronic biological effects of exposure to ionizing radiation.
- Exposure to ionizing radiation can have detrimental effects on cells and the organisms containing the cells. For example, acute radiation syndrome (ARS) is an illness caused by irradiation of the body (either the entire body or a significant portion thereof) to ionizing radiation. ARS includes four phases: a prodromal period, a latent period, and a period of illness, followed by recovery or death. During the prodromal period, individuals can experience loss of appetite, nausea, vomiting, fatigue, and diarrhea, and additional symptoms such as fever and respiratory distress may occur after exposure to extremely high doses. These symptoms typically disappear after a day or two, and a symptom-free period follows, with a length depending on the size of the radiation dose. The third period, overt illness, can include characteristics such as infection, electrolyte imbalance, diarrhea, bleeding, and cardiovascular collapse. Finally, death or recovery follows the illness. Delayed effects of acute radiation syndrome (DEARE) also can occur from non-lethal but high acute doses of ionizing radiation. Symptoms are largely tissue-specific, but generally manifest as degenerative diseases, including cardiovascular disease, cognitive impairment, and fibrosis of various tissues, for example. Acute or chronic exposure to low doses of radiation also is a concern. Low doses of radiation, while not being acutely toxic, may still cause irreparable genomic mutations that can increase the risk of cancer later in life, as well as the risk of cardiovascular disease, tissue fibrosis, inflammation, and neurodegenerative conditions.
- This document is based, at least in part, on the discovery that compositions containing genistein can be useful as countermeasures against the ionizing effects of radiation, and particularly against the ionizing effects of neutron and charged particle radiation. Genistein has significant cell-signaling activities that affect how cells respond to radiation damage. As described herein, compositions (e.g., suspension formulations) that contain genistein nanoparticles as the active ingredient may be used as countermeasures against exposure to ionizing radiation, decreasing DNA damage, oxidation, and other adverse effects. In some embodiments, therefore, the methods described herein can be used to mitigate acute and delayed effects in individuals exposed to radiation that induces ionizing events. In some embodiments, the methods described herein also can be used to protect individuals at risk of exposure to radiation that induces ionizing events, preventing or reducing the adverse effects should exposure to such radiation occur.
- In one aspect, this document features a method for preventing, reducing, or mitigating, in a subject in need thereof, one or more effects of exposure to proton radiation. The method can include administering to the subject a composition containing nanoparticulate genistein, where the subject is identified as having been exposed to proton radiation or as being at risk of exposure to proton radiation, and where the composition has a nanoparticulate genistein concentration between about 250 mg/mL and about 500 mg/mL. The subject can be a human (e.g., a cancer patient who will undergo proton radiation therapy, an individual who will be traveling to outer space, a first responder, or a member of the military). The genistein nanoparticulate composition can have a particle size distribution characterized by a d(0.5) less than or equal to 0.3 μm. The composition further can contain one or more pharmaceutically acceptable excipients forming a suspension medium, where the one or more pharmaceutically acceptable excipients include a water soluble polymer containing a polyvinylpyrrolidone. The one or more pharmaceutically acceptable excipients can include a nonionic surfactant, a diluent, or a buffer. The nonionic surfactant can be present in an amount ranging from about 0.01% to about 10% by weight (w/w). The amount of water soluble polymer can be about 0.5% to about 15% (w/w). The composition can contain a diluent and a preservative, and optionally can further comprise a non-ionic surfactant. The nanoparticulate genistein can be present in the composition at an amount ranging up to about 50% (w/w), or at an amount of about 20% to about 35% (w/w). The composition can have a nanoparticulate genistein concentration of about 325 mg/mL. The composition can have a pH of about 2 to about 12. The composition can be formulated as a tablet, a capsule, or a gel cap.
- The method can include administering the composition orally, intramuscularly, subcutaneously, or intravenously. The method can include administering the composition about 2 hours before potential exposure to the proton radiation, within about 48 hours before potential exposure to the proton radiation, or within about 24 hours before potential exposure to the proton radiation. The can include administering the composition on a daily basis. The method can include administering the composition at a dose of about 0.5 g to about 2.5 g, or at a dose of about 1 g to about 1.5 g. The method can include administering the composition within about 60 minutes after exposure to the proton radiation, or within about 24 hours after exposure to the proton radiation. The method can include administering the composition at a dose of about 0.5 g to about 2.5 g per day for about 1 day to about 90 days.
- In another aspect, this document features the use of a composition containing nanoparticulate genistein for preventing, reducing, or mitigating, in a subject in need thereof, one or more effects of exposure to proton radiation, wherein the subject is identified as having been exposed to proton radiation or as being at risk of exposure to proton radiation, and wherein the composition has a nanoparticulate genistein concentration between about 250 mg/mL and about 500 mg/mL. The subject can be a human. The subject can be a cancer patient who will undergo proton radiation therapy, a subject who will be traveling to outer space, a first responder, or a member of the military. The genistein nanoparticulate composition can have a particle size distribution characterized by a d(0.5) less than or equal to 0.3 μm. The composition can further contain one or more pharmaceutically acceptable excipients forming a suspension medium, wherein the one or more pharmaceutically acceptable excipients include a water soluble polymer comprising a polyvinylpyrrolidone. The one or more pharmaceutically acceptable excipients can include a nonionic surfactant, a diluent, or a buffer. The nonionic surfactant can be present in an amount ranging from about 0.01% to about 10% by weight (w/w). The amount of water soluble polymer can be about 0.5% to about 15% (w/w). The composition can contain a diluent and a preservative. The composition can further contain a non-ionic surfactant. The nanoparticulate genistein can be present in the composition at an amount ranging up to about 50% (w/w), or at an amount of about 20% to about 35% (w/w). The composition can have a nanoparticulate genistein concentration of about 325 mg/mL. The composition can have a pH of about 2 to about 12. The composition can be formulated as a tablet, a capsule, or a gel cap. The composition can be formulated for oral, intramuscular, subcutaneous, or intravenous use. The composition can be formulated for administration about 2 hours before potential exposure to the proton radiation, formulated for administration within about 48 hours before potential exposure to the proton radiation, or formulated for administration within about 24 hours before potential exposure to the proton radiation. The composition can be formulated for administration on a daily basis. The composition can be formulated for administration at a dose of about 0.5 g to about 2.5 g, or at a dose of about 1 g to about 1.5 g. The composition can be formulated for administration within about 60 minutes after exposure to the proton radiation, or for administration within about 24 hours after exposure to the proton radiation. The composition can be formulated for administration at a dose of about 0.5 g to about 2.5 g per day for about 1 day to about 90 days.
- Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
- The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
-
FIG. 1 is a schematic depicting how genistein may mitigate the deleterious effects of ionizing radiation. For example, x-rays generally mediate their damaging effects via indirect/oxidative effects, as the ionization of water can create reactive oxygen species (ROS). Free radical scavenging by genistein may prevent this damage. Particle radiation involving a particles, β particles, neutrons, and protons typically causes moderate amounts of both indirect and direct damage, while high energy nuclei (HZE) radiation exerts the majority of its negative consequences via direct effects. The physical properties of these particles tend to cause a significant amount of secondary ionization events (delta rays) that concentrate the damage caused by the radiation along the beam path. Thus, on a per-beam (or dose-equivalent) manner, one transit of a cell by HZE radiation can have devastating consequences on the cellular components. These direct effects may be mitigated by genistein. Genistein's affinity for estrogen receptor type β (ERβ) over ERα generally is antagonistic to ER signaling, and suppresses growth pathways in favor of activating cellular checkpoints, which can give cells sufficient time to enact DNA repair. This may be replicated by genistein's tyrosine kinase inhibition, which also is causative of delaying the cell cycle in favor of DNA repair following cellular damage. -
FIG. 2 is a western blot with heart and lung tissue extracted from animals that were treated with or without genistein [200 mg/kg subcutaneously (s.c.)] and then exposed to 6 Gy high LET proton radiation 24 hours after treatment. The indicated tissues were harvested 3 days later. The levels of p53 (a DNA damage response protein) and γH2AX (a direct measurement of DNA damage) were measured and compared to a tubulin control. In both tissues, genistein treatment prevented a marked increase in p53 levels in response to the radiation exposure. Genistein treatment also was correlated with lower levels of γH2AX. These results implied that genistein mitigates the toxicity from proton radiation. -
FIG. 3A is a graph plotting quantification of the western blot data for heart tissue as shown inFIG. 2 .FIG. 3B is a graph plotting quantification of the western blot data for lung tissue as shown inFIG. 2 . -
FIGS. 4A, 4B, and 4C are graphs plotting the levels of CXCL1 cytokine (FIG. 4A ), granulocyte colony stimulating factor (G-CSF;FIG. 4B ), and tumor necrosis factor alpha (TNFα;FIG. 4C ) in blood from mice injected with 200 mg/kg genistein (s.c.) 24 hours prior to exposure to 6 Gy high LET proton radiation. In these experiments, blood was drawn from mice on the indicated days following radiation exposure, and the levels of cytokines were assayed. -
FIG. 5 is a graph plotting the number of live human cardiomyocytes after treatment of the cells with genistein 24 hours before exposure to various doses of mixed field (32% neutron, 68% gamma) radiation (henceforth referred to as “MF” radiation). Live cell counts were performed 3 days after radiation exposure. The genistein-treated cells exhibited increased survival after exposure to multiple doses of MF radiation. These data imply that genistein treatment can mitigate damage from MF radiation that includes particle radiation. - As used herein, the term “ionizing radiation” refers to forms of radiation that can induce ionizing events within a cell. Individuals may encounter various forms of ionizing radiation, including alpha, beta, neutron, gamma, proton, and x-ray radiation. Ionizing radiation forms ions in cells of the tissues through which it passes, by removing electrons from atoms and molecules. Different types of radiation have varying levels of energy—typically, the more energy a type of radiation has, the more deeply it can penetrate into tissue.
- Each type of ionizing radiation has a typical source. For example, alpha, beta, and gamma radiation are all created by the natural process of radioactive decay. Neutron radiation generally is caused by atomic fission or fusion, and may be encountered in nuclear power plants, in cosmic or high-altitude flight, or from industrial radioactive sources. X-rays are man-made and are generated for clinical purposes.
- The physical properties of radiation and their sources underlie the distinction between the various types. For example, gamma rays are high energy photons, and have no appreciable mass or charge. X-rays also are high energy photons, but are distinguished by their source since they are generally created by man-made instruments. In contrast, non-gamma types of ionizing radiation consist of various atomic particles, including neutrons, protons, alpha particles, beta particles, and high energy nuclei (HZE), and have distinct physical properties, including the mass of each particle. Because these non-photonic, particle types of radiation all have mass and energy, they can be related to one another by their linear energy transfer (LET), which describes how much energy an ionizing particle transfers to material that it traverses, per unit distance.
- Alpha radiation consists of ejected helium nuclei, which are heavy, very short-range particles containing two protons and two neutrons. Most alpha radiation is not able to penetrate human skin, although alpha-emitting materials can be harmful to humans if inhaled, swallowed, or absorbed through open wounds. Examples of alpha emitters include radium, radon, uranium, and thorium.
- Beta radiation consists of ejected electrons or positrons, which are light, short-range particles that may travel several feet in air. Beta radiation has the ability to penetrate human skin to the “germinal layer” at which new skin cells are produced. Beta-emitting materials that are allowed to remain on the skin for a prolonged period of time may cause skin injury, and may be harmful if deposited internally. Examples of beta emitters include strontium-90, carbon-14, tritium, and sulfur-35.
- Neutron radiation consists of free neutrons released from atoms as a result of nuclear fission or nuclear fusion. Free neutrons have no charge, but can react with nuclei of other atoms to form new isotopes, which, in turn, can produce radiation.
- Proton radiation can be generated using a particle accelerator to produce a beam of protons. Protons have a relatively large mass, and all protons of a given energy have a certain range of penetration into tissue. Because of this feature, proton radiation can be useful for highly targeted treatment of tumors. Proton radiation also is a significant component of the ionizing radiation produced by the sun.
- HZE radiation consists of atomic nuclei with an atomic mass greater than helium that have no orbiting electrons, and thus have a charge of greater than +2. They can be generated by large particle accelerators, and are only found in nature as a component of galactic cosmic radiation, presumed to be generated mainly by supernovas beyond Earth's solar system. Common HZE ions include C+6, O+8, and Fe+26. The frequency of HZE nucleons is inversely proportional to their atomic number, but the relative biological effect scales with increasing atomic number. For example, while Fe+26 may only
makeup 1% of galactic cosmic radiation, it could account for up to 50% of the biological damage from exposure to such radiation. - Radiation in nature typically is encountered as a mixed field (MF) that contains multiple types of radiation, rather than as a single beam exposure of the type commonly created by man. MF radiation can include various combinations of proton radiation, neutron radiation, alpha and/or beta radiation, and photon radiation. For example, in the event of an unshielded nuclear fission event (e.g., an attack or a reactor meltdown), individuals would likely be exposed to a miasma of photons, neutrons, alpha, and beta particles.
- The physical differences between various types of ionizing radiation underlie their respective toxicities. For example, when gamma radiation passes through a cell, much of the resulting damage is mediated indirectly via oxidation of water, rather than through direct ionization of biological material. When charged particle radiation contacts a cell, not only is there an oxidative component to the toxicity, but secondary events also can occur as the radiation particles pass through the cellular material. These secondary ionizations (delta rays) occur when electrons are displaced by the primary radiation beam and travel perpendicularly to the primary axis of the ray until they are absorbed. The frequency of delta ray production is dependent on the LET. The more delta rays that are produced, the more localized damage occurs along the track of the primary particle. Thus, secondary ionization events can cause highly localized complex damage to biological material, and can surpass the oxidative component of the toxicity. Thus, equivalent doses of different forms of radiation can have dramatically different biological consequences. The varying consequences of different forms of radiation can be described by Relative Biological Effect (RBE), which serves simply as a multiplier to relate one form to another.
- As different forms of ionizing radiation are differentially toxic to human biology, so too are there different therapeutic modalities for treating or preventing such toxicities. For example, some radiation countermeasures are free-radical scavengers, which can detoxify radiation exposure by limiting oxidative damage. While this may be an avenue for treatment of photon radiation exposure, the complex biological damage resulting from, for example, HZE radiation limits the effectiveness of countermeasures that possess antioxidant activity. Thus, the efficacy of a countermeasure against some forms of ionizing radiation does not predict its efficacy against all forms of ionizing radiation.
- Because of radiation's ionizing effects on cells, exposure to radiation can have detrimental consequences, posing health risks to exposed individuals. The risks of terrestrial exposure to ionizing radiation include, for example, ARS, and DEARE, such as carcinogenesis, damage to the central nervous system, and degenerative effects on tissue, such as fibrosis. Ionizing radiation encountered during space missions also can present potential health problems for astronauts, with a significant risk of ARS (Wu et al., “Risk of Acute Radiation Syndromes Due to Solar Particle Events.” In: McPhee and Charles (Eds.), Human Health and Performance Risks of Space Exploration Missions, NASA, pp. 171-190, 2009). Radiation exposure from the space environment also may increase the risk of cancer morbidity or mortality risk in astronauts (Cucinotta and Durante, “Risk of Radiation Carcinogenesis.” In: McPhee and Charles (Eds.), Human Health and Performance Risks of Space Exploration Missions, NASA, pp. 119-170, 2009). The most likely ARS effects from SPE exposure in space flight, which could affect mission success, include prodromal effects (nausea, vomiting, anorexia, and fatigue), skin injury, and depletion of blood-forming organs. SPEs are of lower energy than are GCRs, and shielding typically is an effective countermeasure to SPEs inside spacecraft. Exposure is likely to be higher during extravehicular activity, however, and the magnitude of ARS risks may be increased due to factors such as background GCR exposure (Wu et al., supra).
- Given the health risks of ionizing radiation, it is important to mitigate the effects of exposure in subjects who have been exposed to, or are at risk of exposure to, ionizing radiation. Those who are most likely to be exposed to ionizing radiation include, for example, cancer patients treated with radiation therapy (e.g., gamma radiation or proton radiation), workers in nuclear power plants, military personnel, and first responders to nuclear incidents (e.g., medical personnel and hazmat teams). Another group of individuals who may encounter ionizing radiation includes astronauts, since ionizing radiation exists in outer space. During space travel, astronauts are exposed to various types of radiation, including galactic cosmic rays (GCR) that are composed of proton radiation and charged HZE nuclei, and solar particle events that mostly consist of proton radiation protons (Sridharan et al., Radiation Res 183:1-26, 2015) but may also include other types of radiation. GCRs can be difficult to shield against, given their high energies. SPEs, which are produced in the solar corona and are associated with flares, can be difficult to predict beyond a matter of hours in advance, and can last for hours or even days (Hassler et al., Science 343(6169), DOI: 10.1126/science.1244797, 2014). It is thought that every cell nucleus within an astronaut traveling to Mars would be traversed by a proton or secondary electron every few days, and by an HZE ion every few months (Cucinotta et al., Radiat Meas 31:181-191, 1998).
- As described herein, compositions containing genistein can be used as medical countermeasures that can reduce or prevent detrimental effects of exposure to ionizing radiation, and in some cases, can increase survival after such exposure. Genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one (IUPAC), 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one, 5,7,4′-trihydroxyisoflavone, 4′,5,7-trihydroxyisoflavone) is a phytoestrogen in the category of isoflavones. Its chemical structure is shown in Formula (1):
- Genistein is one of several known isoflavones that are normally found in plants. The main sources of natural genistein are soybeans and other legumes. Genistein also is commercially available, and may be obtained in synthetic, purified form (e.g., from DSM Nutritional Products, Inc., Parsippany, N.J.).
- Genistein's radioprotective properties may be mediated, at least in part, by its activity as a selective agonist of estrogen receptor beta (ERβ). ERβ activation can inhibit cell proliferation via upregulation of its target genes, which encode cellular checkpoint and damage repair proteins. Other pharmacological properties of genistein that may mediate radioprotection include tyrosine kinase inhibition and free-radical scavenging, as depicted in
FIG. 1 . - As described herein, a formulation of genistein that can be distinguished from other radioprotectants and sources of genistein can be used to mitigate toxicities from various sources of radiation, including proton radiation (e.g., high LET proton radiation). In some embodiments, a composition can include genistein nanoparticles, which can have improved oral and/or parenteral bioavailability as compared to genistein that is not in nanoparticle form. Nanoparticle formulations can contain sub-micron size genistein particles, which can be manufactured using a wet nanomilling process that reduces genistein to a median particle size of less than 0.2 μm. See, e.g., U.S. Pat. No. 8,551,530. Pharmacokinetic experiments using such a genistein nanosuspension in mice demonstrated dramatically increased oral bioavailability as compared to formulations containing non-micronized genistein. See, FIGS. 4-7 of U.S. Pat. No. 8,551,530.
- In some cases, the genistein compositions used in the methods provided herein can be formulations that include genistein in a solution containing one or more pharmaceutically acceptable carriers, excipients, and/or diluents. In some embodiments, the genistein compositions used in the methods provided herein can be suspension formulations that include nanoparticulate genistein suspended in a medium containing one or more pharmaceutically acceptable carriers, excipients, and/or diluents. Pharmaceutically acceptable carriers, excipients, and diluents suitable for therapeutic use include those described, for example, in Remington's Pharmaceutical Sciences, Maack Publishing Co. (A. R. Gennaro (ed.), 1985). In some cases, polyethylene glycol (PEG) can be used as a carrier in a composition that also contains genistein that is not in nanoparticle form.
- In some embodiments, genistein compositions can include a suspension containing nanoparticulate genistein suspended in a non-aqueous medium, such as an edible plant or animal oil (e.g., olive oil, sunflower oil, corn oil, soy oil, marine oil, coconut oil, palm oil, palm kernel oil, cotton seed oil, safflower oil, sesame oil, peanut oil, almond oil, cashew oil, pecan oil, pine nut oil, macadamia oil, orange oil, flax seed oil, lemon oil, walnut oil, borage oils, fish oils, and dairy derived fats). See, e.g., U.S. Pat. No. 9,084,726.
- Genistein compositions can, in some embodiments, include a suspension containing nanoparticulate genistein suspended in a medium including one or more water soluble polymers and one or more nonionic surfactants. See, e.g., U.S. Pat. No. 8,551,530.
- Nonionic surfactants can facilitate wetting and aid in preventing agglomeration of the nanoparticulate genistein, for example. Suitable nonionic surfactants include, without limitation, polysorbates, poloxamers, polyoxyethylene castor oil derivatives, bile salts, lecithin, 12-hydroxystearic acid-polyethylene glycol copolymer, and the like. In some embodiments, a genistein composition can include a nonionic surfactant selected from the group consisting of polysorbate 80 (TWEEN® 80), polysorbate 20 (TWEEN® 20), Poloxamer 188, and combinations thereof. The total nonionic surfactant content in the genistein compositions provided herein can range from about 0.01% to about 10% by weight (w/w) (e.g., about 0.2% to about 5% (w/w), about 0.2% to about 2% (w/w), about 0.2% to about 1% (w/w), about 0.2% to about 0.6% (w/w), and about 0.2% to about 0.8% (w/w).
- Water soluble polymers can serve to enhance the viscosity of a suspension and/or to stabilize nanoparticulate genistein against particle agglomeration or potential deleterious effects from other formulation components, for example. Water soluble polymers are pharmaceutically acceptable polymers that can be dissolved or dispersed in water. Suitable water soluble polymers include, without limitation, vegetable gums (e.g., alginates, pectin, guar gum, and xanthan gum), modified starches, polyvinylpyrrolidone (PVP), hypromellose (HPMC), methylcellulose, and other cellulose derivatives (e.g., sodium carboxymethylcellulose, hydroxypropylcellulose, and the like). In some embodiments, the genistein compositions described herein can include a poloxamer (e.g., Poloxamer 188) as a water soluble polymer. Poloxamer 188 is both a polymer and surfactant. The total water soluble polymer content in a genistein composition as provided herein can range from about 0.5% to about 15% (w/w) [e.g., about 1% to about 10% (w/w), about 10% to about 15% (w/w), about 12% to about 15% (w/w), about 1% to about 8% (w/w), and about 1% to about 5% (w/w)].
- Carriers suitable for use in the genistein formulations described herein also include pharmaceutically acceptable aqueous carriers such as, sterile water, physiologically buffered saline, Hank's solution, and Ringer's solution. The formulations also can contain one or more buffers [e.g., one or more citrate buffers, phosphate buffers, tris(hydroxymethyl)aminomethane (TRIS) buffers, and/or borate buffers], to achieve a desired pH and osmolality. Injectable pharmaceutical formulations typically have a pH in the range of about 2 to about 12. In some embodiments, the genistein formulations provided herein can have a pH that falls in a range that more closely approximates physiologic pH (e.g., about 4 to about 8, or about 5 to about 7).
- The genistein compositions provided herein also can include one or more diluents. Suitable diluents include those selected from, without limitation, pharmaceutically acceptable buffers, solvents, and surfactants.
- In some embodiments, a genistein composition can include PVP (e.g., 5% PVP-K17) and polysorbate 80 (e.g., 0.2% polysorbate 80), as well as phosphate buffered saline (PBS, e.g., 50 nM PBS). In some cases, an oral formulation of a genistein composition can contain PVP (e.g., PVP-K25), polysorbate 80 (TWEEN® 80), and one or more preservatives (e.g., methyl paraben, propyl paraben, benzyl alcohol, or any combination thereof). In addition, a composition can include a diluent such as a sodium chloride solution. The particle size distribution of the genistein nanoparticulate composition can be d(0.5)≤0.50 microns (e.g., d(0.5)≤0.40 microns, d(0.5)≤0.30 microns, or d(0.5)≤0.20 microns). See, e.g., U.S. Pat. No. 8,551,530. It is to be noted that while such genistein formulations are characterized as suspensions, depending on the carriers, excipients, and diluents included in the suspension medium, a measurable amount of genistein also may be dissolved in the suspension medium.
- Genistein exhibits low to virtually no solubility in several pharmaceutically acceptable solvents, but a nanoparticulate suspension of genistein as described herein can provide a high concentration of genistein. For example, a suspension of nanoparticulate genistein can incorporate genistein in amounts ranging from about 100 mg/mL to about 500 mg/mL (e.g., ranges from about 100 mg/mL to about 400 mg/mL, about 150 mg/mL to about 350 mg/mL, about 200 mg/mL to about 400 mg/mL, about 250 mg/mL to about 350 mg/mL, about 275 mg/mL to about 325 mg/mL, about 300 mg/mL to about 450 mg/mL, or about 350 mg/mL to about 500 mg/mL, or amounts of about 100 mg/mL, about 150 mg/mL, about 200 mg/mL, about 250 mg/mL, about 275 mg/mL, about 300 mg/mL, about 325 mg/mL, about 350 mg/mL, about 375 mg/mL, about 400 mg/mL, about 450 mg/mL, or about 500 mg/mL). The relative amount of genistein included in such a suspension can be varied to yield a formulation having a desired total content of genistein. For example, a suspension formulation as described herein can include up to about 50% (w/w) genistein [e.g., about 50% (w/w), about 45% (w/w), about 40% (w/w), about 35% (w/w), about 30% (w/w), about 25% (w/w), about 20% (w/w), about 15% (w/w), about 10% (w/w), about 40% to about 50% (w/w), about 35% to about 45%, about 30% to about 40% (w/w), about 25% to about 35% (w/w), about 20% to about 30% (w/w), about 20% to about 35% (w/w), about 15% to about 35%, about 10% to about 30%, or about 10% to about 25%1. In some embodiments, nanoparticle genistein suspensions can provide increased bioavailability of genistein as compared to the bioavailability of genistein provided by solution formulations (e.g., solutions containing a pharmaceutically acceptable PEG solvent or containing larger sized genistein material). As described in U.S. Pat. No. 8,551,530, for example, the combination of high genistein loading and significantly increased bioavailability can provide advantages, such as facilitating administration of therapeutically effective amounts of genistein using much lower amounts of formulated drug substance, for example.
- Genistein compositions can be formulated for administration by any suitable method, depending upon whether local or systemic treatment is desired and upon the area to be treated. For example, a genistein composition can be formulated for oral administration, parenteral administration (e.g., by subcutaneous, intrathecal, intraventricular, intramuscular, or intraperitoneal injection, or by intravenous drip), pulmonary administration (e.g., by inhalation or insufflation of powders or aerosols or a nebulized mist), or by a combination of routes such as oral and parenteral administration. Administration can be rapid (e.g., by injection) or can occur over a period of time (e.g., by slow infusion or administration of slow release formulations, such as from subcutaneous drug depots, slow short term intravenous injections, or slow release oral formulations).
- Compositions and formulations for parenteral administration include, for example, sterile solutions (e.g., sterile aqueous solutions or suspensions) that also can contain buffers, diluents, and/or other suitable additives (e.g., penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers). Compositions formulated for parenteral delivery can be manufactured according to standard methods to provide sterile compositions deliverable via, for example, intravenous injection or infusion, intravascular injection, subcutaneous injection, or intramuscular injection. A genistein formulation (e.g., a suspension of nanoparticulate genistein) can be prepared to have a viscosity suitable for the desired route of parenteral administration, and can be manufactured and packaged in any manner suited to the desired application, including, without limitation, as a formulation deliverable via intravenous injection or infusion, intravascular injection, subcutaneous injection, or intramuscular injection. In some embodiments, a formulation as described herein can be contained in one or more pre-filled syringes or auto-injectors prepared for administration of a given dose or range of doses of genistein.
- Genistein compositions also can be formulated for oral administration. Compositions and formulations for oral administration include, for example, powders or granules, suspensions or solutions in water or non-aqueous media (e.g., suspensions of genistein nanoparticles in edible oil), capsules, gel caps, sachets, and tablets. In some embodiments, a genistein composition can be prepared as a liquid suspension that can be metered to deliver a desired dose, or can be incorporated into capsules (e.g., gelatin or soft capsules) suitable for delivery of liquid formulations. Alternatively, formulations for oral administration can be loaded into prefilled sachets or premetered dosing cups. In some embodiments, such genistein formulations also can include one or more pharmaceutically acceptable sweetening agents, preservatives, dyestuffs, flavorings, or any combination thereof.
- Genistein compositions useful in the methods described herein can further include any pharmaceutically acceptable genistein salts, esters, or salts of such esters, or any other genistein compound which, upon administration to an animal such as a human, is capable of providing (directly or indirectly) biologically active genistein or an active metabolite or residue thereof. Accordingly, for example, provided herein are pharmaceutically acceptable salts of genistein, prodrugs and pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. The term “prodrug” indicates a therapeutic agent that is prepared in an inactive form and is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. The term “pharmaceutically acceptable salts” refers to physiologically and pharmaceutically acceptable salts of genistein (e.g., salts that retain the desired biological activity of genistein without imparting undesired toxicological effects). Examples of pharmaceutically acceptable salts may include, for example, salts formed with cations (e.g., sodium, potassium, calcium, or polyamines such as spermine), acid addition salts formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, or nitric acid), and salts formed with organic acids (e.g., glucuronic acid, acetic acid, citric acid, oxalic acid, palmitic acid, or fumaric acid). Depending on the route of administration, for example, genistein may be sulfated or in glucuronic acid form.
- Compositions also can include other adjunct components conventionally found in pharmaceutical compositions. Thus, the compositions also can include compatible, pharmaceutically active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or additional materials useful in physically formulating various dosage forms of the compositions provided herein, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. Furthermore, the composition can be mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings, and aromatic substances. When added, however, such materials should not unduly interfere with the biological activities of the genistein within the composition. The formulations can be sterilized if desired.
- This document also provides methods for using genistein compositions as countermeasures against the effects of ionizing radiation. Such countermeasures can be used to prevent, reduce, or mitigate effects such as carcinogenesis, damage to the central nervous system, degenerative effects on tissue, and even death.
- In some embodiments, for example, this document provides methods for treating a subject to prevent, reduce, or mitigate one or more effects of potential exposure to ionizing radiation. The methods can include identifying a subject as being at risk for exposure to ionizing radiation, and administering to the subject an effective dose of a genistein-containing composition. The subject can be, for example, a human or a non-human mammal. Subjects at risk for exposure to ionizing radiation may be individuals who will undergo radiation therapy (e.g., proton therapy) for cancer, individuals present or likely to be present in an industrial or military setting in which exposure to ionizing radiation could occur, or astronauts. In some cases, such individuals can be treated with a genistein-containing composition prophylactically, before exposure to ionizing radiation has occurred. In some embodiments, an individual can be treated on a daily or weekly basis (e.g., every day, about six days per week, about five days per week, about four days per week, about three days per week, or about two days per week), before potential exposure to ionizing radiation. In some embodiments, an individual can be treated within about 1 hour to about 6 days (e.g., within about 5 to 6 days, about 4 to 5 days, about 3 to 4 days, about 60 to 72 hours, about 48 to 60 hours, about 36 to 48 hours, about 24 to 36 hours, about 18 to 24 hours, about 12 to 18 hours, about 10 to 12 hours, about 8 to 10 hours, about 6 to 8 hours, about 4 to 6 hours, about 2 to 4 hours, or about 1 to 2 hours) before potential exposure, such as before entering an area of increased risk for exposure to ionizing radiation or before an imminent SPE event, to prevent or reduce potential harmful effects, should such exposure occur.
- In some embodiments, this document provides methods for treating a subject to reduce, prevent, or mitigate one or more effects of exposure to ionizing radiation. The methods can include identifying a subject as having been exposed to ionizing radiation (e.g., exposed once, exposed more than once, such as for fractionated proton radiation therapy for cancer treatment, or exposed continuously over a period of time), and administering to the subject an effective dose of a genistein-containing composition. In some embodiments, the subject can be a human or a non-human mammal, and can be an individual exposed to ionizing radiation in a medical setting (e.g., a cancer patient treated with proton radiation therapy) or in an industrial or military setting, or in outer space. Such subjects can be treated on an hourly, daily, or weekly basis after exposure, in order to mitigate harmful effects of exposure to the ionizing radiation. In some embodiments, the genistein composition can be administered within about four weeks or less (e.g., within about three weeks, two weeks, or one week), or within about 96 hours or less (e.g., within about 72 to 96 hours, about 48 to 72 hours, about 24 to 48 hours, about 20 to 24 hours, about 18 to 20 hours, about 16 to 18 hours, about 12 to 16 hours, about 8 to 12 hours, about 6 to 8 hours, about 4 to 6 hours, or about 2 to 4 hours), or within about 60 minutes or less (e.g., within about 45 to 60 minutes, about 30 to 45 minutes, about 15 to 30 minutes, about 10 to 15 minutes, or about 5 to 10 minutes) after exposure. Administration can continue on an hourly, daily, weekly, or monthly basis to mitigate the effects of exposure to the ionizing radiation. For example, a genistein-containing composition can be administered one or more times daily, every other day, biweekly, weekly, bimonthly, monthly, or less often, for any suitable length of time after exposure to the radiation has occurred (e.g., for about a week, about two weeks, about three weeks, about a month, about six weeks, about two months, about three months, about six months, about a year, or more than a year after exposure).
- The methods provided herein include administering to a subject a composition that contains genistein in any formulation suitable to deliver an effective dose of genistein to the subject, where the dose is effective to prevent, reduce, or mitigate effects of the ionizing radiation to which the subject has been or may be exposed. As used herein, a dose administered that is “effective to reduce” the effects of the radiation is a dose that is sufficient to decrease one or more effects of exposure (should such exposure occur) by at least ten percent (e.g., at least ten percent, at least 25 percent, at least 50 percent, or at least 75 percent) as compared to the level of the effects in a corresponding subject to which the composition was not administered. In some embodiments, an effective dose can prevent development of one or more effects of exposure to the ionizing radiation. As used herein, a dose administered that is “effective to mitigate” the effects of ionizing radiation is a dose that is sufficient to reduce the effects of exposure by at least ten percent (e.g., at least ten percent, at least 25 percent, at least 50 percent, or at least 75 percent), as compared to a corresponding subject to which the composition was not administered. Effective doses (e.g., therapeutically or prophylactically effective doses) can be effective to prevent, reduce, or mitigate effects of exposure to ionizing radiation that include, without limitation, ARS effects, carcinogenesis, central nervous system damage, degenerative effects on tissue, and death.
- In some embodiments, a composition can contain genistein (e.g., nanoparticulate genistein or genistein that is not in nanoparticle form), at a concentration between about 100 mg/mL and about 500 mg/mL (e.g., about 100 mg/mL to about 400 mg/mL, about 150 mg/mL to about 350 mg/mL, about 200 mg/mL to about 400 mg/mL, about 250 mg/mL to about 350 mg/mL, about 275 mg/mL to about 325 mg/mL, about 300 mg/mL to about 450 mg/mL, or about 350 mg/mL to about 500 mg/mL). Compositions containing nanoparticulate genistein can have a particle size distribution characterized by a median diameter [d(0.5)] that is less than or equal to 0.5 μm (e.g., less than or equal to 0.4 μm, less than or equal to 0.3 μm, or less than or equal to 0.2 μm). The composition also can contain one or more other components, as described herein (e.g., one or more pharmaceutically acceptable excipients that form a suspension medium, such as a water soluble polymer, a nonionic surfactant, a diluent, or a buffer). In some embodiments, the suspension medium may be non-aqueous, such as edible lipids, oils, and fats from plant and animal sources (e.g., olive, corn, soy, marine, coconut, palm, palm kernel, cotton seed, peanut, safflower, sesame, sunflower, almond, cashew, macadamia, pecan, pine nut, walnut, lemon, orange, flax seed, and borage oils).
- The administering step can be accomplished via any suitable route. In some embodiments, for example, a genistein composition containing a solution of genistein or a suspension of genistein nanoparticles can be administered orally or parenterally (e.g., by injection, such as subcutaneous, intravenous, or intramuscular injection).
- In some embodiments, a prophylactic or therapeutic dose of a genistein-containing composition can contain about 0.25 g to about 2.5 g of genistein (e.g., about 0.25 g to about 0.3 g, about 0.3 g to about 0.4 g, about 0.4 g to about 0.5 g, about 0.5 g to about 0.75 g, about 0.75 g to about 1 g, about 1 g to about 1.25 g, about 1.25 g to about 1.5 g, about 1.5 g to about 1.75 g, about 1.75 g to about 2 g, about 2 g to about 2.25 g, or about 2.25 g to about 2.5 g). In some cases, a dose of a genistein-containing composition can be effective to achieve a blood concentration of aglycone (unconjugated, non-glucuronidated) genistein of about 0.35 μM to about 5 μM (e.g., about 0.5 μM, about 1 μM, about 1.5 μM, about 2 μM, about 3 μM, about 4 μM, about 5 μM, about 0.35 to about 0.5 μM, about 0.5 to about 0.75 μM, about 0.75 to about 1 μM, about 0.75 to about 1.25 μM, about 1 to 1.5 μM, about 1.5 to 2.5 μM, or about 2.5 to 5 μM).
- In some embodiments, a genistein composition can be administered to a subject at a dose of about 5 mg/kg to about 500 mg/kg (e.g., about 5 to 10 mg/kg, about 10 to 25 mg/kg, about 25 to 50 mg/kg, about 50 mg/kg, about 75 to 100 mg/kg, about 100 to 200 mg/kg, about 200 to 300 mg/kg, about 300 to 400 mg/kg, or about 400 to 500 mg/kg). The dose can be administered on a daily to weekly to monthly basis or longer (e.g., for about 1 day to about 2 years, such as from 1 to 3 days, 3 to 7 days, 7 to 10 days, 10 to 14 days, 14 to 21 days, 21 to 28 days, 28 to 35 days, 30 to 45 days, 45 to 60 days, two to three months, three to six months, six to nine months, nine months to a year, one to 1.5 years, 1.5 to 2 years, or more than 2 years).
- In some embodiments, a therapeutic method can include administering a first dose of genistein for a first period of time after exposure to ionizing radiation, and then administering a second dose of genistein for a second period of time. The first dose can be higher than the second dose. For example, a method can include administering a genistein-containing composition at a dose of 0.25 g to about 2.5 g per day (e.g., about 0.25 g to about 0.3 g, about 0.3 g to about 0.4 g, about 0.4 g to about 0.5 g, about 0.5 g to about 0.75 g, about 0.75 g to about 1 g, about 1 g to about 1.25 g, about 1.25 g to about 1.5 g, about 1.5 g to about 1.75 g, about 1.75 g to about 2 g, about 2 g to about 2.25 g, or about 2.25 g to about 2.5 g per day) for about 1 day to about 6 months (e.g., about 1 day to about 3 days, about 3 days to about 7 days, about 7 days to about 2 years, such as from 7 to 10 days, 10 to 14 days, 14 to 21 days, 21 to 28 days, 28 to 35 days, 30 to 45 days, 45 to 60 days, two to three months, or three to six months), and then administering the composition at a dose of about 0.1 g to about 1 g per day (e.g., about 0.1 g to about 0.7 g, 0.2 g to about 0.5 g, about 0.3 g to about 1 g, about 0.5 g to about 0.8 g, or about 0.5 g to about 1 g) for about 1 day to about 2 years (e.g., from 1 to 3 days, 3 to 7 days, 7 to 10 days, 10 to 14 days, 14 to 21 days, 21 to 28 days, 28 to 35 days, 30 to 45 days, 45 to 60 days, two to three months, three to six months, six to nine months, nine months to a year, one to 1.5 years, or 1.5 to 2 years).
- This document also provides for the use of genistein compositions as described herein for preventing, reducing, or mitigating one or more effects of exposure to proton radiation in a subject identified as having been exposed to proton radiation or as being at risk of exposure to proton radiation. In addition, this document provides for the use of genistein in the manufacture of medicaments for preventing, reducing, or mitigating one or more effects of exposure to proton radiation in a subject identified as having been exposed to proton radiation or as being at risk of exposure to proton radiation.
- Genistein formulations (e.g., genistein solutions or nanoparticle suspensions) can be combined with packaging material and sold as kits for preventing, reducing, or mitigating the effects of exposure to ionizing radiation. Thus, this document also provides articles of manufacture that can include one or more genistein-containing compositions. The articles of manufacture can further include, for example, buffers or other control reagents for reducing, preventing, or monitoring the effects of exposure to ionizing radiation. Instructions describing how genistein formulations are effective for preventing, reducing, or mitigating damage from such exposure also can be included in such kits.
- In some embodiments, an article of manufacture can include a genistein formulation (e.g., a suspension of nanoparticulate genistein) contained within a means for administration, such as an auto-injector. For example, an auto-injector can contain a suspension of nanoparticulate genistein at a concentration between about 250 mg/mL and about 500 mg/mL, where the genistein nanoparticulate composition has a particle size distribution characterized by a d(0.5) of 0.5 μm or less (e.g., 0.4 μm or less, 0.3 μm or less, or 0.2 μm or less). The genistein composition also can include other components (e.g., one or more pharmaceutically acceptable excipients), as described herein.
- Components and methods for producing articles of manufacture include those known in the art, for example. In addition, in some embodiments, pre-made auto-injectors can be obtained commercially, filled with a genistein nanoparticulate composition, and packaged as a kit for preventing, reducing, or mitigating the effects of exposure to ionizing radiation.
- The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.
- Mice were prophylactically administered genistein (200 mg/kg) via s.c. injection 24 hours prior to radiation exposure. Appropriate sham radiation and vehicle controls were applied. Radiation exposures of 6 Gy with high-LET protons [50 MeV fully modulated spread-out Bragg peak (SOBP)] were utilized. The following parameters were examined:
- DNA damage in tissues—Lungs and heart were surgically removed and subjected to thin-slice sectioning, followed by western blot analysis for the DNA damage markers p53 and γH2AX (an effective measure of proton radiation-induced biological damage; see, Liu et al., Radiation Oncology 91(5):1081-1089, 2015), as well as tubulin control. Genistein ameliorated the effects of proton radiation on expression of these markers (
FIGS. 2, 3A, and 3B ), indicating its ability to mitigate the toxicity of proton radiation. - Cytokine response—Peripheral blood was taken from the treated and irradiated
mice 3, 6, and 12 days after radiation exposure, and assessed using a multi-cytokine LUMINEX® panel to evaluate the global inflammatory cytokine response. As shown inFIGS. 4A, 4B, and 4C , specific cytokine responses were reduced by genistein treatment. In particular genistein mitigated the effects of proton radiation on expression of CXCL1 cytokine (FIG. 4A ), G-CSF (FIG. 4B ), and TNFα (FIG. 4C ). - Human cardiomyocytes were treated with genistein 24 hours before exposure to various doses of mixed field (“MF,” 32% neutron, 68% gamma) radiation. Live cell counts were performed 3 days after radiation exposure. The genistein-treated cells exhibited increased survival after exposure to multiple doses of MF radiation (
FIG. 5 ). These data imply that genistein treatment can mitigate damage from MF radiation that includes particle radiation, and indicate that genistein is consistent in its radioprotective effects. - A cancer-prone genetic mouse model is utilized to determine if oral administration of 200 mg/kg genistein prevents an increased incidence in radiation-induced cancer after exposure to simulated space radiation. The space radiation simulations include various single ion beams, and mixed fields therein, which are produced at Brookhaven National Laboratory to simulate various spectra of space radiation. Readouts include the incidence of cancers of various tissues in each animal, overall survival, and lifespan.
- Cognitive defects from ionizing radiation are known to result in humans undergoing radiotherapy for brain tumors. To determine whether genistein can reduce the occurrence of such defects, subjects likely to be exposed to various spectra of ionizing radiation are treated with oral genistein at a dose sufficient to achieve a blood concentration of aglycone (unconjugated, non-glucuronidated) genistein of about 1 μM. Consumption of genistein can be beneficial to mitigating such cognitive toxicity if it is consumed before, during, and/or after radiation exposure. Radiation exposure could range from clinical proton therapy in cancer patients to GCR exposure in space-travelling astronauts. The protective capacity of genistein on cognitive function is tested using standard cognitive tests.
- The protective effects of genistein oral administration also are tested in nonclinical animals models (e.g., mice). Genistein (200 to 400 mg/kg) is orally administered to mice up to 7 days before radiation exposure, and possibly continuing for up to about 6 weeks after radiation exposure. At specific time intervals following radiation exposure and administration of genistein, the animals are subjected to validated cognitive function tests, such as the “Delayed, Non-Matching to Place Task,” or the “Conditioned Eyeblink Reflex,” as well as brain histopathological analyses to be conducted at necropsy of the test subject.
- Further studies are conducted to evaluate genistein's in vivo protective effect against proton radiation when administered prophylactically. Mice are prophylactically orally gavaged with a daily dose of 400 mg/kg genistein, starting one to six days prior to radiation exposure. The prophylactic dose regimen consists of either a single daily dose of 400 mg/kg, or two daily doses of 200 mg/kg each. Appropriate sham radiation and vehicle controls are applied. The mice are sacrificed for analysis either 4 hours or 16 days after radiation treatment, and assessed for the parameters listed below. Study groups include five mice per condition, with two time points and two dosing schemes, requiring 30 animals/experiment. Initial studies include irradiating the mice at 6Gy with high-LET protons (50 MeV fully modulated spread-out Bragg peak (SOBP)), and subsequent experiments are conducted with 4, 2, and 0.5 Gy doses in an effort to determine any threshold of radiation-exposure efficacy.
- The in vivo studies include analysis of any or all of the following parameters.
- 1. Hematopoietic blood cell count. Complete blood cell (CBC) counts (WBC, ANC, and platelets) are determined 16 days post radiation exposure in the genistein-treated and untreated groups. This time point corresponds to the nadir in irradiated animals and thus provides a critical time point to evaluate genistein's efficacy.
- 2. Cytokine response. Peripheral blood is taken from the animals and assessed using a multi-cytokine LUMINEX® panel to assess the global inflammatory cytokine response. Peripheral blood is collected for cytokine analysis 4 hours and 16 days post radiation exposure.
- 3. DNA damage in tissues. Lungs, liver, and bowel from sacrificed animals (4 hours and 16 days post radiation exposure) are surgically removed and subjected to thin-slice sectioning, followed by immunohistological analysis for γH2AX, which has been demonstrated to be an effective measure of proton radiation-induced biological damage (Liu et al., Radiation Oncology 91(5):1081-1089, 2015). Additionally, pathological parameters such as fibrosis and evidence of inflammation are qualitatively assessed. Tissue analysis is performed on sections from groups of animals demonstrating therapeutic efficacy by CBC measures.
- 4. DNA damage markers in white blood cells. Peripheral blood is collected at 4 hours and 16 days post radiation exposure. White blood cells are purified and assessed for DNA damage markers, such as p53 and γH2AX, which are detected by FACS or western blot.
- It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims (20)
1. A method for reducing or mitigating, in a subject in need thereof, one or more deleterious effects of exposure to mixed field radiation, wherein the method comprises administering to the subject a composition comprising an active ingredient and one or more pharmaceutically acceptable excipients, wherein the active ingredient comprises genistein, wherein the subject is identified as having been exposed to mixed field radiation or as being at risk of exposure to mixed field radiation, and wherein the composition is effective to reduce or mitigate the one or more deleterious effects of mixed field radiation in the subject, and wherein the one or more deleterious effects are one or more of acute radiation syndrome (ARS), delayed effects of acute radiation syndrome, cardiovascular disease, tissue fibrosis, inflammation, and neurodegenerative conditions.
2. The method of claim 1 , wherein the subject is a human.
3. The method of claim 1 , wherein the subject is a first responder or is a member of the military.
4. The method of claim 1 , wherein the genistein is nanoparticulate genistein.
5. The method of claim 4 , wherein the nanoparticulate genistein has a particle size distribution characterized by a d(0.5) less than or equal to 0.3 μm.
6. The method of claim 1 , wherein the one or more pharmaceutically acceptable excipients form a suspension medium, and wherein the one or more pharmaceutically acceptable excipients include a water soluble polymer comprising a polyvinylpyrrolidone.
7. The method of claim 1 , wherein the one or more pharmaceutically acceptable excipients include a nonionic surfactant, a diluent, or a buffer.
8. The method of claim 1 , wherein the composition comprises a diluent and a preservative.
9. The method of claim 8 , wherein the composition further comprises a non-ionic surfactant.
10. The method of claim 1 , wherein the genistein is present in the composition at an amount ranging up to about 50% (w/w).
11. The method of claim 10 , wherein the genistein is present in the composition at an amount of about 20% to about 35% (w/w).
12. The method of claim 1 , wherein the composition has a genistein concentration of about 325 mg/mL.
13. The method of claim 1 , wherein the composition is formulated as a powder, a granule, a tablet, a capsule, or a gel cap.
14. The method of claim 1 , comprising administering the composition orally, intramuscularly, subcutaneously, or intravenously.
15. The method of claim 1 , comprising administering the composition within about 48 hours before potential exposure to the mixed field radiation.
16. The method of claim 1 , comprising administering the composition on a daily basis.
17. The method of claim 1 , comprising administering the composition at a dose of about 5 mg/kg to about 500 mg/kg.
18. The method of claim 1 , comprising administering the composition within about 24 hours after exposure to the mixed field radiation.
19. The method of claim 1 , comprising administering the composition at a dose of about 5 mg/kg to about 500 mg/kg per day for about 1 day to about 90 days.
20. The method of claim 1 , wherein the mixed field radiation comprises 32% neutron radiation and 68% gamma radiation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/890,809 US20220401375A1 (en) | 2017-02-24 | 2022-08-18 | Protecting tissue and mitigating injury from radiation-induced ionizing events |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762463340P | 2017-02-24 | 2017-02-24 | |
PCT/US2018/019507 WO2018156946A1 (en) | 2017-02-24 | 2018-02-23 | Protecting tissue and mitigating injury from radiation-induced ionizing events |
US201916488325A | 2019-08-23 | 2019-08-23 | |
US17/890,809 US20220401375A1 (en) | 2017-02-24 | 2022-08-18 | Protecting tissue and mitigating injury from radiation-induced ionizing events |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/019507 Continuation WO2018156946A1 (en) | 2017-02-24 | 2018-02-23 | Protecting tissue and mitigating injury from radiation-induced ionizing events |
US16/488,325 Continuation US11419827B2 (en) | 2017-02-24 | 2018-02-23 | Protecting tissue and mitigating injury from radiation-induced ionizing events |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220401375A1 true US20220401375A1 (en) | 2022-12-22 |
Family
ID=63253446
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/488,325 Active US11419827B2 (en) | 2017-02-24 | 2018-02-23 | Protecting tissue and mitigating injury from radiation-induced ionizing events |
US17/890,809 Pending US20220401375A1 (en) | 2017-02-24 | 2022-08-18 | Protecting tissue and mitigating injury from radiation-induced ionizing events |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/488,325 Active US11419827B2 (en) | 2017-02-24 | 2018-02-23 | Protecting tissue and mitigating injury from radiation-induced ionizing events |
Country Status (2)
Country | Link |
---|---|
US (2) | US11419827B2 (en) |
WO (1) | WO2018156946A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11779644B2 (en) | 2017-09-29 | 2023-10-10 | Humanetics Corporation | Sensitizing cells to proton radiation |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3465153A (en) * | 1964-08-14 | 1969-09-02 | Mc Donnell Douglas Corp | Radiation protection system and apparatus |
US6094760A (en) | 1997-08-04 | 2000-08-01 | Sumitomo Heavy Industries, Ltd. | Bed system for radiation therapy |
DE602004017479D1 (en) | 2003-08-29 | 2008-12-11 | Pfizer | THIENOPYRIDINPHENYLACETAMIDES SUITED AS NEW ANTIANGIOGENIC AGENTS AND DERIVATIVES THEREOF |
BRPI0414011A (en) | 2003-08-29 | 2006-10-24 | Pfizer | naphthalencarboxamides and their derivatives useful as new antiangiogenic agents |
US20070293458A1 (en) * | 2006-06-16 | 2007-12-20 | Ip-6 Research Inc. | Prevention of nuclear, solar, and other radiation-induced tissue damage |
US8557290B2 (en) | 2008-03-14 | 2013-10-15 | Northwestern University | Multifunction nanoconjugates for imaging applications and targeted treatment |
EA201290846A1 (en) * | 2010-03-01 | 2013-07-30 | Интраоп Медикал Корпорейшн | RADIOT THERAPY COMBINED WITH HYPOXIC CELL SENSITIZERS |
US8900635B2 (en) * | 2010-11-15 | 2014-12-02 | Humanetics Corporation | Nanoparticle isoflavone compositions and methods of making and using the same |
WO2013032591A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
CA2854563A1 (en) | 2011-11-11 | 2013-05-16 | Woomera Therapeutics | Provasopressin antagonists and uses thereof |
CN104736181A (en) | 2012-08-10 | 2015-06-24 | 北德克萨斯大学健康科学中心 | Drug delivery vehicle comprising conjugates between targeting polyamino acids and fatty acids |
US10679730B2 (en) | 2013-05-28 | 2020-06-09 | The University Of Chicago | Prognostic and predictive breast cancer signature |
US9623004B2 (en) | 2013-08-02 | 2017-04-18 | Humanetics Corporation | Administration of a therapeutic amount of genistein to mitigate erectile dysfunction resulting from radiation therapy for prostate cancer only throughout a defined administration period commencing shortly before and concluding after radiation therapy |
US20150126597A1 (en) | 2013-11-07 | 2015-05-07 | Humanetics Corporation | Genistein cancer treatment regimen maximizing cancer radiation therapy benefits |
US9084726B2 (en) | 2013-11-26 | 2015-07-21 | Humanetics Corporation | Suspension compositions of physiologically active phenolic compounds and methods of making and using the same |
US11129894B2 (en) | 2017-09-29 | 2021-09-28 | - Humanetics Corporation | Sensitizing cells to proton radiation |
-
2018
- 2018-02-23 WO PCT/US2018/019507 patent/WO2018156946A1/en active Application Filing
- 2018-02-23 US US16/488,325 patent/US11419827B2/en active Active
-
2022
- 2022-08-18 US US17/890,809 patent/US20220401375A1/en active Pending
Non-Patent Citations (1)
Title |
---|
https://www.atomicarchive.com/science/effects/radiation.html retrieved on 12 January 2023. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11779644B2 (en) | 2017-09-29 | 2023-10-10 | Humanetics Corporation | Sensitizing cells to proton radiation |
Also Published As
Publication number | Publication date |
---|---|
US20190380972A1 (en) | 2019-12-19 |
US11419827B2 (en) | 2022-08-23 |
WO2018156946A1 (en) | 2018-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pietrofesa et al. | Radiation mitigating properties of the lignan component in flaxseed | |
Obrador et al. | Nuclear and radiological emergencies: biological effects, countermeasures and biodosimetry | |
US20220401375A1 (en) | Protecting tissue and mitigating injury from radiation-induced ionizing events | |
Breccia et al. | On the chemical radioprotection by organic selenium compounds in vivo | |
Farhood et al. | Mitigation of radiation-induced gastrointestinal system injury using resveratrol or alpha-lipoic acid: a pilot histopathological study | |
Hsu et al. | Difference in the effects of radioprotection between aerial and root parts of Lycium chinense | |
Reiter et al. | Melatonin protection from chronic, low-level ionizing radiation | |
Carnell et al. | Evidence report: risk of acute radiation syndromes due to solar particle events | |
Cole et al. | Age, strain and species factors in post-irradiation protection by spleen homogenates | |
Patel et al. | Long-term deficits in behavior performances caused by low-and high-linear energy transfer radiation | |
US20210244751A1 (en) | Methods and compositions for protection of cells and tissues from computed tomography radiation | |
JP2016534057A (en) | Methods for treating and preventing radiation injury | |
US20150231093A1 (en) | Methods and compositions for countermeasures against radiation | |
Amirfakhrian et al. | The use of 99mTc-phytate for assessment the protective effect of vitamin E against hepatotoxicity induced by methotrexat in rat | |
Upton et al. | Chemical protection of the mouse against leukemia induction by roentgen rays | |
US20170000761A1 (en) | Protecting tissue and mitigating injury from chemical exposure | |
Medvedovsky et al. | The influence of dose, dose-rate and particle fragmentation on cataract induction by energetic iron ions | |
Mian et al. | Plutonium dispersal and health hazards from nuclear weapon accidents | |
Cox et al. | Late cataractogenesis in primates and lagomorphs after exposure to particulate radiations | |
US20060223880A1 (en) | Methods of protecting against radiation injury | |
Odeblad | A Study on the Protective Action of 2, 3-Dimercaptopropanol (BAL) on Radiation-Induced Changes in the Ovarian Follicles in Mice | |
US20180243327A1 (en) | USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION DAMAGE | |
Spiers et al. | Radioactivity of the human body | |
CN107412239B (en) | Application of the glibenclamide in preparation protection induced lung injury drug | |
Mohamed et al. | Role of PLGA-nanoparticles formulation to improve drug radioprotective activity in gamma-irradiated mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: HUMANETICS CORPORATION, MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HARVEY, ADAM J.;KAYTOR, MICHAEL D.;DYKSTRA, JOHN C.;SIGNING DATES FROM 20191202 TO 20191212;REEL/FRAME:062696/0107 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |